

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the understanding and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1196/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1196" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the understanding and treatment of acute myeloid leukemia" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the understanding and treatment of acute myeloid leukemia.">
            <meta name="og:description" content="Read the latest article version by Justin Watts, Stephen Nimer, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15353">
            <meta name="article-id" content="14116">
            <meta name="dc.title" content="Recent advances in the understanding and treatment of acute myeloid leukemia">
            <meta name="dc.description" content="Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.">
            <meta name="dc.subject" content="acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development">
            <meta name="dc.creator" content="Watts, Justin">
            <meta name="dc.creator" content="Nimer, Stephen">
            <meta name="dc.date" content="2018/08/06">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14116.1">
            <meta name="dc.source" content="F1000Research 2018 7:1196">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/06">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1196">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14116.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1196">
            <meta name="citation_title" content="Recent advances in the understanding and treatment of acute myeloid leukemia">
            <meta name="citation_abstract" content="Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.">
            <meta name="citation_description" content="Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.">
            <meta name="citation_keywords" content="acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Justin Watts">
            <meta name="citation_author_institution" content="Sylvester Comprehensive Cancer Center and Miller School of Medicine, University of Miami, Miami, Florida, USA">
            <meta name="citation_author" content="Stephen Nimer">
            <meta name="citation_author_institution" content="Sylvester Comprehensive Cancer Center and Miller School of Medicine, University of Miami, Miami, Florida, USA">
            <meta name="citation_publication_date" content="2018/08/06">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1196">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14116.1">
            <meta name="citation_firstpage" content="1196">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1196/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1196.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15353 /> <input type=hidden id=articleId name=articleId value=14116 /> <input type=hidden id=xmlUrl value="/articles/7-1196/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1196-v1.xml"> <input type=hidden id=article_uuid value=67b78820-765c-43f1-a69e-691ec0708ff9 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the understanding and treatment of acute myeloid leukemia"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14116.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14116.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1196"
  },
  "headline": "Recent advances in the understanding and treatment of acute myeloid leukemia",
  "datePublished": "2018-08-06T10:10:57",
  "dateModified": "2018-08-06T10:10:57",
  "author": [
    {
      "@type": "Person",
      "name": "Justin Watts"
    },    {
      "@type": "Person",
      "name": "Stephen Nimer"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1196/v1",
            "name": "Recent advances in the understanding and treatment of acute myeloid..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the understanding and treatment of acute myeloid... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15353 data-id=14116 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14116.1" data-recommended="" data-doi="10.12688/f1000research.14116.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1196/v1/pdf?article_uuid=67b78820-765c-43f1-a69e-691ec0708ff9" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14116-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14116-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14116-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Watts J and Nimer S. Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1196 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14116.1" target=_blank>https://doi.org/10.12688/f1000research.14116.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14116-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14116 id=track-article-signin-14116 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14116?target=/articles/7-1196/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15353 /> <input name=articleId type=hidden value=14116 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the understanding and treatment of acute myeloid leukemia</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:jxw401@miami.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Justin Watts</span></a><a href="https://orcid.org/0000-0001-5213-5482" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5213-5482</div>,&nbsp;</span><span class="">Stephen Nimer</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:jxw401@miami.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Justin Watts</span></a><a href="http://orcid.org/0000-0001-5213-5482" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5213-5482</div>,&nbsp;</span><span class="">Stephen Nimer</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 06 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14116.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Sylvester Comprehensive Cancer Center and Miller School of Medicine, University of Miami, Miami, Florida, USA<br/> <p> <div class=margin-bottom> Justin Watts <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Writing – Original Draft Preparation </div> <div class=margin-bottom> Stephen Nimer <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37155-36497></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37154-36496></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37153-36495></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Justin Watts (<a href="mailto:jxw401@miami.edu">jxw401@miami.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Justin Watts </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Justin Watts has served as a consultant and on the Speaker’s Bureau for Jazz Pharmaceuticals. He has received research funding from Takeda. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The authors receive support from a Leukemia and Lymphoma Society (LLS) Specialized Center of Research (SCOR) Grant (Stephen Nimer [principal investigator] and Justin Watts), NIH-NCI R01CA166835 (Stephen Nimer), NIH-NCI R21CA202488 (Justin Watts), and a University of Miami Clinical and Translational Science Institute KL2TR000461 Grant (Justin Watts). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Watts J and Nimer S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Watts J and Nimer S. Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1196 (<a href="https://doi.org/10.12688/f1000research.14116.1" target=_blank>https://doi.org/10.12688/f1000research.14116.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 06 Aug 2018, <b>7</b>(F1000 Faculty Rev):1196 (<a href="https://doi.org/10.12688/f1000research.14116.1" target=_blank>https://doi.org/10.12688/f1000research.14116.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 06 Aug 2018, <b>7</b>(F1000 Faculty Rev):1196 (<a href="https://doi.org/10.12688/f1000research.14116.1" target=_blank>https://doi.org/10.12688/f1000research.14116.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e159>Introduction</h2><p class="" id=d33828e162>While the past 10 to 20 years witnessed an explosion in the number of US Food and Drug Administration (FDA)-approved therapies for lymphoid malignancies, myeloid drug development lagged behind, and few drugs were approved, particularly for acute myeloid leukemia (AML). This was puzzling in light of similar, if not greater, advances in the understanding of the genetic basis and pathophysiology of myeloid malignancies, which represent about 5% of all adult cancers<sup><a href="#ref-1">1</a></sup>. The challenge of translating these scientific discoveries into effective therapies for patients with AML or myelodysplasia constituted an urgent unmet medical need. However, the FDA has recently approved three new drugs for AML and re-approved gemtuzumab ozogamicin (GO), all in 2017, offering encouragement that more breakthroughs are coming, commensurate to our biological understanding of myeloid neoplasia. This review focuses on AML pathogenesis and recent therapeutic advances, including the genetic heterogeneity of AML, the critical role that epigenetic abnormalities play in its development, promising pre-clinical drug targets and ongoing clinical trials, and the recently approved new agents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e172>Background</h2><p class="" id=d33828e175>AML is primarily a disease of older adults with a median age at diagnosis of about 70 years<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. It is the most common leukemia after chronic lymphocytic leukemia and is the leading cause of leukemia-related deaths in the US<sup><a href="#ref-1">1</a></sup>. Overall, AML is fatal for the majority of patients (~80%), and modern cooperative group studies show that patients younger than 55 to 60 years of age have about 40% 5-year survival but that those older than 60 have an abysmal less than 5% to 10% 5-year survival<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. Until very recently, the standard chemotherapy for AML remained largely unchanged for decades, and the survival improvements over time in younger patients were attributable mostly to better supportive care and safer/improved hematopoietic stem cell transplantation (HSCT) techniques<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. Outcomes have remained particularly poor and without significant improvement in older adults since the 1970s<sup><a href="#ref-6">6</a></sup>. In addition to host factors, adverse biological features are common in older patients, making AML a challenge to treat in this patient population. Consequently, we have seen rising AML mortality rates as the aging population continues to increase<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a></sup> despite some improvements in the treatment of younger patients. Clearly, new and better therapies are urgently needed for AML, particularly for older patients.</p><p class="" id=d33828e215>The clinical responses seen with all-<i>trans</i> retinoic acid (ATRA) in acute promyelocytic leukemia (APL), subsequently found to reflect the presence of the PML-RARα translocation fusion product, and the incredible success of imatinib in t(9;22) chronic myeloid leukemia (CML), driven by the BCR-ABL tyrosine kinase, led many to believe that identifying single genetic abnormalities in myeloid cancers would predict response to targeted therapies. However, we now know that, in most clinical settings, only a small fraction of patients will respond to targeted therapies. For example, we know very well that only some AML patients with <i>FLT3</i>-internal tandem duplication (<i>FLT3</i>-ITD) mutations respond to kinase inhibitors, only some with del(5q) myelodysplastic syndromes (MDSs) respond to lenalidomide, and only some with isocitrate dehydrogenase 2 (<i>IDH2</i>) mutations respond to IDH2 inhibitors. In many cases, even patients who initially respond to targeted therapies rapidly develop resistance. This is likely due to a variety of factors, including epigenetic changes and the type and number of co-occurring genetic mutations. In this review, we will present these challenges and how to potentially solve them.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e233>Genetic heterogeneity and epigenetic deregulation in acute myeloid leukemia</h2><p class="" id=d33828e236>While the total number of genetic mutations and frequency of chromosomal aneuploidy are less in AML than in most solid tumors, AML remains a remarkably genetically heterogeneous disease<sup><a href="#ref-8">8</a></sup>. Diverse combinations of specific driver mutations have a clear effect on prognosis. In a landmark study, Patel <i>et al</i>. reported that a comprehensive assessment of the major co-occurring mutations in AML significantly impacts prognosis and treatment<sup><a href="#ref-9">9</a></sup>. Indeed, this work, plus decades of laboratory and clinical research, has convincingly demonstrated that it is the constellation of mutations in AML that determines prognosis and responsiveness to therapy. Considering this fundamental principle, translational researchers have created mouse models combining these different lesions, such as those expressing AML1-ETO (AE) in <i>Tet2</i><sup>+/–</sup> cells or <i>Asxl2</i><sup>+/–</sup> cells or expressing FLT3-ITD in <i>Tet2</i><sup>+/–</sup> cells in order to better reflect and determine which treatments may work in which AML patient subtypes.</p><p class="" id=d33828e266>Another seminal paper recently described 11 unique genomic/mutational classes of AML, with additional (non-class-defining) driver mutations co-occurring within each class, such as <i>FLT3</i>-ITD, resulting in dozens of AML subtypes which may each require a unique multi-agent therapy<sup><a href="#ref-10">10</a></sup>. Furthermore, in addition to DNA sequence mutations, AML has been increasingly recognized as an epigenetically driven disease. While most patients have at least one mutation in an epigenetic modifying protein, essentially all patients with AML have deregulated epigenetic regulation of multiple pathways as a hallmark<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. Because the effect of combinatorial genetic mutations on chromatin structure and DNA methylation is not simply additive, accurate, disease-predicting, pre-clinical models remain extremely valuable as we attempt to increase the therapeutic index of novel, epigenetic-focused treatments. Combinations of mutations clearly interact to drive the initiation and progression of AML and may create unique sensitivities to epigenetic-focused and other targeted or chemo-therapies. For example, co-occurring <i>IDH2</i> and <i>DNMT3A</i> mutations result in a distinct DNA methylation pattern different from what is seen with either mutation alone (“epigenetic antagonism”), leading to upregulation of Ras signaling and unique sensitivity to MEK inhibition in <i>IDH2</i>/<i>DNMT3A</i> double-mutants<sup><a href="#ref-11">11</a></sup>. Multifaceted studies that can define epigenetic or gene expression signatures that are associated with responsiveness to specific therapies should translate into improved therapies for patients with myeloid malignancies.</p><p class="" id=d33828e300>Though clinically heterogeneous, a wealth of genome-wide studies point to epigenetic deregulation as the major driver of the myeloid malignancies<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup>. In fact, we now know that mutations in <i>ASXL1</i>, <i>ASXL2</i>, <i>TET2</i>, <i>DNMT3A</i>, and <i>IDH1/2</i> occur more commonly in MDS and AML than do chromosomal translocations, which also target key transcription factors and epigenetic regulators. The reversibility of epigenetic changes, unlike that of genetic changes, provides an opportunity to potentially treat virtually all leukemias (and cancers) using epigenetic-focused approaches. Given the speed at which epigenetic-focused therapeutics are being formulated, accurate pre-clinical models that can identify predictive molecular signatures and carefully constructed clinical trials of epigenetic-focused agents in rigorously defined patient populations are greatly needed. To achieve success, we need to continue to create new reagents and more accurately model the multitude of gene mutations found in patients with AML, MDS, and MDS/myeloproliferative neoplasm (MPN).</p><p class="" id=d33828e326>This review will focus on the promise of epigenetic therapies but also on novel chemotherapy agents, antibody-drug conjugates, and kinase inhibitors that either are FDA approved or appear promising in clinical trials. However, it is the combination of epigenetic agents used together or with other agents that holds the most promise of making AML a more successfully treatable disease, like APL and CML.</p><p class="" id=d33828e330>Additionally, while inhibition of overexpressed/disease-promoting—for example, enhancer of zeste homolog 2 (EZH2), protein arginine methyltransferases (PRMTs), and lysine-specific demethylase 1 (LSD1)—and neomorphic/gain-of-function epigenetic enzymes (such as IDH1/2) is clearly important, the predominantly decreased activity of <i>mutated</i> epigenetic enzymes in myeloid diseases provides at least three additional unique therapeutic possibilities that have been understudied to date: (1) successfully restoring normal enzymatic function by boosting the function of the remaining functional allele; (2) triggering the complete loss of enzymatic function, triggering cell death, which may be more readily accomplished in cells with only one normal allele; and (3) deleting an epigenetic gene to create a unique sensitivity to manipulating targets in an interacting pathway. Exploring these possibilities represents a rapidly evolving new area of AML research.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e339>Targeting epigenetics in acute myeloid leukemia (pre-clinical drug targets)</h2><p class="" id=d33828e342>AML is a clinically heterogeneous disease driven by diverse pathogenic lesions, including somatic mutations, chromosomal defects, and epigenetic changes observed in primary patient samples. Epigenetic deregulation, which is due in part to somatic mutations in epigenetic regulators, is a hallmark of the pathogenesis of myeloid malignancies. The reversibility of epigenetic changes, even when driven by underlying genetic alterations, suggests that improvements in outcome should be achievable by tailoring treatments to the underlying epigenetic defects. In this section, we will review novel epigenetic targets being studied in the laboratory in order to rapidly identify new therapies for patients. We already have clinical evidence that epigenetic therapies are active in AML. However, given the complexity of epigenetic interactions in AML and the number of potentially co-occurring sensitizing or resistance-conferring mutations, often within the same patient or even the same cell, and potentially unanticipated drug effects on epigenetic regulation, combination AML therapy with different classes of drugs will likely remain the hallmark of AML treatment but with more epigenetic-targeted agents being incorporated into existing and emerging treatment paradigms.</p><div class=section><a name=d33828e345 class=n-a></a><h3 class=section-title>TET2</h3><p class="" id=d33828e350>TET2 is a dioxygenase enzyme using alpha-ketoglutarate (αKG), Fe<sup>2+</sup>, and O<sub>2</sub> for hydroxylation of DNA methylcytosine (5mC), converting it into 5-hydroxymethylcytosine (5hmC), which can be converted into other derivatives, including ultimately demethylated DNA. <i>TET2</i> is one of the most commonly mutated genes in myeloid malignancies, and <i>TET2</i> mutations are also found in apparently hematologically normal individuals with clonal hematopoiesis<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. <i>TET2</i> mutations are commonly an ancestral mutational event and, as such, constitute a suitable target for intervention in the early stages of hematopoietic stem cell/hematopoietic progenitor cell (HSC/HPC) expansion. <i>Tet2</i> loss/haploinsufficiency in HSCs/HPCs leads to MDS/MPN development in mice and cooperates with other disease alleles (for example, AML1-ETO or <i>FLT3</i>-ITD) to induce AML<sup><a href="#ref-15">15</a>–<a href="#ref-18">18</a></sup>. Specifically, <i>Tet2</i> loss leads to increased HSC self-renewal and skewed differentiation toward the monocytic lineage<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. TET2 catalytic activity is required for its function as a myeloid leukemia tumor suppressor in HSCs/HPCs<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d33828e404> <i>TET2</i> mutations are mostly heterozygous, resulting in enzymatic haploinsufficiency, leading to decreased 5hmC and concomitantly increased 5mC. Therefore, a compelling therapeutic strategy is to augment TET2 function by increasing the enzymatic activity of the remaining wild-type allele. To split O<sub>2</sub> for dioxygenation, TET2 requires three electrons: two from αKG and one from vitamin C<sup><a href="#ref-15">15</a></sup>. Agents such as dimethyl 2-oxoglutarate (DMKG) and vitamin C augment TET2 enzymatic activity <i>in vitro</i> and in mouse models and hold the potential to restore TET2 activity<sup><a href="#ref-19">19</a></sup>. The phenotype of Tet2 restoration, which is mimicked by vitamin C treatment, includes reversal of aberrant hematopoietic stem and progenitor cell (HSPC) self-renewal and restoration of hypomethylation, differentiation, and cell death<sup><a href="#ref-19">19</a></sup>. Activators of TET2 catalytic activity, such as vitamin C, are capable of reversing the leukemic-transforming ability of <i>TET2</i> haploinsufficiency and thus represent promising combination partners with other therapies, such as DNA hypomethylating agents (HMAs) and p300 inhibitors<sup><a href="#ref-19">19</a></sup>. Cimmino <i>et al</i>. have also shown that TET-mediated DNA oxidation induced by vitamin C treatment in leukemia cells may enhance their sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors<sup><a href="#ref-19">19</a></sup>. Combining vitamin C with HMAs in <i>TET2</i>-mutant (TET2m) MDS to augment their therapeutic potential is now being studied in the clinic. Clinical trials using high-dose intravenous vitamin C in TET2m MDS, with or without concomitant HMA therapy, are now available (ClinicalTrials.gov Identifier: NCT03433781) and this represents an exciting new therapeutic strategy given that TET2m patients already have increased sensitivity to HMAs<sup><a href="#ref-20">20</a></sup>. Given that <i>TET2</i> clonal hematopoiesis of indeterminate potential (CHIP) mutations affect older adults (~5%)<sup><a href="#ref-13">13</a></sup>, the importance of developing TET2-targeted therapies will only become more relevant as the population ages and the incidence of both <i>de novo</i> and therapy-related MDS continues to rise.</p></div><div class=section><a name=d33828e462 class=n-a></a><h3 class=section-title>ASXL1</h3><p class="" id=d33828e467>The Drosophila additional sex-combs (ASX) gene is a chromatin-binding polycomb protein required for embryogenesis. Genomic studies have highlighted that the ASXL (additional sex combs-like) family members ASXL1 and ASXL2 are recurrently mutated in human AML. ASXL1 is mutated (deleted or truncated) at high frequencies in all forms of myeloid malignancy<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>; it is associated with poor prognosis in patients with chronic myelomonocytic leukemia (CMML), MDS, myelofibrosis, and AML<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Thus, therapies targeting mutant <i>ASXL1</i>-bearing cells are sorely needed. In contrast, ASXL2 is specifically mutated in t(8;21) AML<sup><a href="#ref-25">25</a></sup>. Importantly, ASXL1 and ASXL2 mutations occur in a mutually exclusive fashion in t(8;21) AML and, owing to their similarities, it has been hypothesized that there is a shared mechanism of leukemogenesis arising from these two mutations. However, it is still not clear whether mutations in <i>ASXL1</i>/<i>2</i> confer loss-of-function, dominant-negative activity or generate a novel or altered function. Thus, their shared or unique mechanisms in leukemogenesis remain unclear. The majority of the <i>ASXL1</i> mutations are nonsense/frameshift and heterozygous and expected to be loss of function. However, a truncated ASXL1 protein (C-terminus) has been shown to be expressed in cells harboring <i>homozygous</i> mutations of <i>ASXL1</i>, suggesting dominant-negative or even gain-of-function activity<sup><a href="#ref-26">26</a></sup>. Whether mutations in <i>ASXL1</i> generate haploinsufficiency or dominant-negative or gain-of-function proteins (or combinations thereof) is a question with great clinical implications given the highly recurrent and adverse nature of <i>ASXL1</i> mutations in MDS/AML.</p><p class="" id=d33828e518>To this end, various groups have generated model systems to dissect the possible roles of ASXL1/2 alterations in leukemogenesis and identify therapeutic vulnerabilities they may create<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Avenues for identifying drug candidates for <i>ASXL1</i>/<i>2</i>-mutated myeloid malignancies include studying the biological effects of <i>ASXL1</i> versus <i>ASXL2</i> loss in the presence of cooperating mutations such as AML1-ETO.</p></div><div class=section><a name=d33828e541 class=n-a></a><h3 class=section-title>Lysine acetyltransferases</h3><p class="" id=d33828e546>The CBP/p300 coactivator family of histone lysine acetyltransferases (KATs) is another emerging and promising target in myeloid malignances. KATs—and, in particular, CBP/p300—have been shown to play important tumor suppressor and oncogenic roles in cancer<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. Whereas histone deacetylases have been targeted therapeutically in patients with myeloid neoplasms (with modest success), the KAT enzymes have been largely ignored. Since the first nuclear KAT enzyme was isolated 20 years ago<sup><a href="#ref-31">31</a></sup>, exciting data have emerged implicating histone (and non-histone) protein acetylation in regulating gene expression and the pathways that control normal and neoplastic cell growth. CBP and p300 are two related, broadly expressed KAT proteins that have been shown to affect normal HSC self-renewal and differentiation<sup><a href="#ref-29">29</a></sup>. Mutations in the <i>EP300</i> (<i>KAT3B</i>) and <i>CBP</i> (<i>KAT3A</i>) genes have been found in lymphoma, small cell lung cancer, and other solid tumors, identifying their tumor suppressor function<sup><a href="#ref-32">32</a></sup>. p300 can also function as an oncogene in AML<sup><a href="#ref-33">33</a></sup>, melanoma<sup><a href="#ref-34">34</a></sup>, and prostate cancer<sup><a href="#ref-35">35</a></sup>. In fact, there appear to be distinct roles for p300 in mouse models of myeloid malignancies: an oncogenic role in AML1-ETO-driven AML<sup><a href="#ref-33">33</a></sup> and a tumor suppressor role in MDS driven by the NUP98-HOXD13 (NHD13) fusion protein<sup><a href="#ref-36">36</a></sup>. Consequently, p300 may display variable activity, depending on the disease that it initiated. The cell context-specific functions of p300 suggest that developing both agonist and antagonist drugs may be therapeutically relevant.</p><p class="" id=d33828e602><b><i>CBP/p300 inhibitors.</i></b> In 2011, we identified the critical role of p300 in binding to AML1-ETO and the subsequent acetylation of AML1-ETO on K43, which regulates the ability of AML1-ETO to activate gene expression, promote self-renewal, and trigger AML<sup><a href="#ref-33">33</a></sup>. We showed that both pharmacologic inhibition and genetic knockdown of p300 improve the survival of AML1-ETO-bearing mice and that CBP/p300 inhibitors impair the growth of AML1-ETO-expressing (and several other) human leukemia cell lines<sup><a href="#ref-33">33</a></sup>. This suggests that p300/CBP may be critical for leukemia cell self-renewal and that targeting its catalytic activity may have broad therapeutic potential in AML1-ETO-positive AML. The first selective CBP/p300 inhibitor (Lys-CoA) was developed in the 1990s<sup><a href="#ref-31">31</a></sup>, and newer-generation, more potent CBP/p300 inhibitors are in active development and are being studied in pre-clinical cancer models<sup><a href="#ref-37">37</a></sup>. Salicylate derivatives and related anti-inflammatory drugs such as diflunisal have also been demonstrated to inhibit both CBP and p300 and shown anti-leukemic activity in pre-clinical AML models<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d33828e628><b><i>CBP/p300 activators.</i></b> Despite the rarity of the t(2;11)(q31;p15) in MDS, NUP98-HOXD13-driven MDS mice have been studied since 2005 because they accurately reflect the clinical behavior of human MDS<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. This model has been used by us and others to study the role of p53<sup><a href="#ref-40">40</a></sup>, Msi2<sup><a href="#ref-41">41</a></sup>, and p300<sup><a href="#ref-33">33</a>,<a href="#ref-36">36</a></sup> in MDS. Notably, deletion of p300 (but not CBP) markedly accelerated leukemogenesis in the setting of NHD13-driven MDS, as 100% of the NHD13<sup>+</sup>, p300 null mice died from AML within 20 weeks<sup><a href="#ref-36">36</a></sup>. Although NHD13<sup>+</sup> bone marrow (BM) cells demonstrated defective <i>in vitro</i> growth, which is characteristic of MDS, the absence of p300 promoted the growth and self-renewal of these cells despite having little or no effect on normal mouse BM cells. The underlying mechanisms are being actively pursued using this and other mouse models of MDS/AML. Additionally, p300 activators are being investigated in these models. One candidate compound is I-CBP112, a selective and potent p300/CBP bromodomain inhibitor<sup><a href="#ref-42">42</a></sup> that unexpectedly <i>stimulates</i> the acetylation of nucleosomes by both p300 and CBP. Therefore, exposure to I-CBP112 increases H3K18Ac in multiple cancer cell lines<sup><a href="#ref-43">43</a></sup>. I-CBP112 is being assessed for anti-growth properties in myeloid malignancies with subnormal p300/CBP function. Ongoing studies will assess whether restoring p300/CBP function in neoplastic cells will trigger growth arrest or apoptosis.</p></div><div class=section><a name=d33828e683 class=n-a></a><h3 class=section-title>Protein arginine methyltransferases</h3><p class="" id=d33828e688>To date, cancer therapies targeting histone modifications have been directed primarily toward lysine methyltransferases, such as DOT1L and EZH2<sup><a href="#ref-44">44</a></sup>. More recently, the PRMTs have emerged as promising drug targets as well. PRMTs are ubiquitous enzymes and include PRMT1, PRMT4, PRMT5, and PRMT6. Type I PRMTs result in asymmetric arginine dimethylation, whereas type II enzymes catalyze symmetric arginine dimethylation. Most pre-clinical work at this time is focused on PRMT1 (type I), PRMT4 (type I), and PRMT5 (type II). PRMT4, also known as coactivator-associated arginine methyltransferase 1 (CARM1), is a transcriptional regulator with unique histone (H3R17 and H3R26) and non-histone (MLL, splicing factors, SWI/SNF, p300, and RUNX1) targets<sup><a href="#ref-45">45</a></sup>. PRMT4 has been shown to be overexpressed in AML cell lines and patient samples and to block myeloid differentiation, possibly through its effects on RUNX1<sup><a href="#ref-46">46</a></sup>. In pre-clinical models, PRMT4 short hairpin RNA (shRNA) knockdown has been shown to induce apoptosis and differentiation of AML cells. Further studies, with small-molecule PRMT4 inhibitors, are ongoing in AML cell lines and murine models. PRMT5 inhibitors are also under development for potential use in lymphoma, solid tumors, and AML<sup><a href="#ref-45">45</a>,<a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. The PRMTs, particularly PRMT4 (but also PRMT1 and PRMT5), represent an exciting new epigenetic drug target class with the potential to help overcome the myeloid differentiation block and inhibit the aberrant self-renewal seen in AML cells.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e717>Emerging clinical approaches for acute myeloid leukemia in 2017</h2><p class="" id=d33828e720>Four new drugs were FDA approved for AML in 2017: CPX-351, enasidenib, midostaurin, and GO (<a href="#T1">Table 1</a>). These therapies range from targeted single agents (enasidenib, which targets mutant IDH2 [mIDH2] AML) and multi-kinase inhibitors (midostaurin) to a fixed drug combination for induction chemotherapy (CPX-351) and the re-approval of an antibody–drug conjugate that targets CD33 (GO). First, we will briefly review the indications and data behind these new approvals and then we will focus on promising investigational agents and combinations still in development. To induce more durable remissions in patients with AML, particularly for those with relapsed or high-risk disease, we clearly need to initiate rational combination strategies earlier in drug development.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Recently approved and investigational agents in acute myeloid leukemia and related myeloid neoplasms.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d33828e737 class=n-a></a><thead><a name=d33828e739 class=n-a></a><tr><a name=d33828e741 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d33828e743 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d33828e746 class=n-a></a>Drug(s)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d33828e749 class=n-a></a>Approved indication<sup><a href="#FN1">a</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d33828e755 class=n-a></a>Safety</th></tr></thead><tbody><a name=d33828e760 class=n-a></a><tr><a name=d33828e762 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e764 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e767 class=n-a></a>CPX-351</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e770 class=n-a></a>New dx AML-MRC or t-AML</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e773 class=n-a></a>Myelosuppression and<br class=br>hemorrhage</td></tr><tr><a name=d33828e779 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e781 class=n-a></a>CD33</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e784 class=n-a></a>GO</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e787 class=n-a></a>Multiple</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e790 class=n-a></a>Myelosuppression and<br class=br>VOD</td></tr><tr><a name=d33828e796 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e798 class=n-a></a>Mutant<br class=br>FLT3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e803 class=n-a></a>Midostaurin, sorafenib,<br class=br>gilteritinib, and others</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e808 class=n-a></a>New dx FLT3<sup>+</sup> AML in<br class=br>combination with standard<br class=br>induction<sup><a href="#FN1">b</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e821 class=n-a></a>GI and rash</td></tr><tr><a name=d33828e825 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e827 class=n-a></a>Mutant<br class=br>IDH2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e832 class=n-a></a>Enasidenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e835 class=n-a></a>R/R IDH2<sup>+</sup> AML</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e841 class=n-a></a>GI and indirect<br class=br>hyperbilirubinemia</td></tr><tr><a name=d33828e847 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e849 class=n-a></a>Mutant<br class=br>IDH1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e854 class=n-a></a>Ivosidenib, FT-2102,<br class=br>and others</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e859 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e862 class=n-a></a>GI</td></tr><tr><a name=d33828e867 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e869 class=n-a></a>BCL2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e872 class=n-a></a>Venetoclax</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e875 class=n-a></a>No<sup><a href="#FN1">c</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e881 class=n-a></a>Myelosuppression and GI</td></tr><tr><a name=d33828e885 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e887 class=n-a></a>LSD1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e890 class=n-a></a>TCP, IMG-7289, and<br class=br>others</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e895 class=n-a></a>Yes<sup><a href="#FN1">d</a></sup>/No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e902 class=n-a></a>Thrombocytopenia and<br class=br>neuropsychiatric</td></tr><tr><a name=d33828e908 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e910 class=n-a></a>Nedd8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e913 class=n-a></a>Pevonedistat</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e916 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e919 class=n-a></a>Transaminitis</td></tr><tr><a name=d33828e923 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e925 class=n-a></a>Mutant<br class=br>TET2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e930 class=n-a></a>Vitamin C and HMAs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e933 class=n-a></a>No/Yes<sup><a href="#FN1">e</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e939 class=n-a></a>?</td></tr><tr><a name=d33828e943 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e945 class=n-a></a>BET</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e948 class=n-a></a>Multiple</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e951 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d33828e954 class=n-a></a>GI and metabolic</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d33828e962 class=n-a></a><p id=FN1> <sup>a</sup>US Food and Drug Administration (FDA) approved indication for acute myeloid leukemia (AML). <sup>b</sup>Only midostaurin is FDA approved for AML. Sorafenib is FDA approved for other malignancies. Use in AML is off-label but is supported by National Comprehensive Cancer Network (NCCN) guidelines (hypomethylating agent [HMA] combination). <sup>c</sup>Venetoclax is FDA approved for chronic lymphocytic leukemia (CLL). AML use is off-label at this time. <sup>d</sup>TCP (tranylcypromine) is FDA approved, but use in AML is off-label. <sup>e</sup>Azacitidine approved for only myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and low-blast AML in the US (although NCCN guidelines support use in AML patients who are not candidates for induction chemotherapy). In Europe, there are similar approvals for azacitidine and decitabine, but they include all AML. TET2-mutant patients may have increased response rates to HMAs<sup><a href="#ref-19">19</a></sup>. TP53-mutant AML patients may have increased response rates to decitabine 10-day schedule<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; BCL2, B-cell leukemia/lymphoma-2; BET, bromodomain and extra terminal; Dx, diagnosis; IDH, isocitrate dehydrogenase; GI, gastrointestinal; GO, gemtuzumab ozogamicin; LSD1, lysine-specific demethylase 1; R/R, relapsed/refractory; VOD, (hepatic) veno-occlusive disease.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e1000>Newly approved therapies for acute myeloid leukemia</h2><div class=section><a name=d33828e1003 class=n-a></a><h3 class=section-title>CPX-351</h3><p class="" id=d33828e1008>CPX-351 is a dual drug liposomal encapsulation containing a 1:5 molar ratio of daunorubicin/cytarabine, which appears to optimize synergy between the two drugs and promote leukemia cell killing in pre-clinical models<sup><a href="#ref-51">51</a></sup>. Phase I–III trials in AML have demonstrated that the pharmacokinetics of CPX-351 are dramatically different from conventional bolus dose anthracycline and infusional cytarabine (3+7) and that prolonged drug exposure is demonstrable in patient plasma for 24 hours<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. For induction, CPX-351 is given over 90 minutes for three doses on days 1, 3, and 5 (each dose contains 44 mg/m<sup>2</sup> of daunorubicin and 100 mg/m<sup>2</sup> of cytarabine) and this approach confers more prolonged and continuous exposure to daunorubicin than traditional 3+7. CPX-351 liposomes also appear to accumulate preferentially in the marrow relative to other tissues<sup><a href="#ref-54">54</a>–<a href="#ref-56">56</a></sup>.</p><p class="" id=d33828e1035>In a randomized phase III study of 309 patients, Lancet <i>et al</i>. showed that CPX-351 conferred a superior overall survival (OS) advantage compared with traditional 3+7 in older patients (60–75 years old) with newly diagnosed secondary AML (defined as t-AML or evolved from a prior hematologic disorder or the presence of MDS-related cytogenetic abnormalities)<sup><a href="#ref-57">57</a></sup>. Median OS was superior for CPX-351 versus 3+7 (9.6 versus 5.9 months; <i>p</i> = 0.005). CPX-351-treated patients had higher complete remission (CR) rates (38% versus 26%), and more patients in the CPX-351 arm were transplanted in CR1. Patients treated with CPX-351 had increased BM toxicity (delayed count recovery) and increased bleeding events compared with those receiving 3+7, including more fatal central nervous system hemorrhage (2% versus 0.7%). Whether the length of aplasia was the cause of the bleeding risk is not yet fully understood. In contrast, there was less colitis and diarrhea and, anecdotally, less hair loss in the CPX-351 arm, possibly reflecting less extramedullary exposure and toxicity-related CPX-351. It is important to realize that the FDA-approved label for CPX-351 includes all adults (≥18 years old) with t-AML or AML with myelodysplasia-related changes (AML-MRC) and is not limited to older patients. AML-MRC includes patients with a prior diagnosis of MDS or CMML, MDS-related cytogenetic changes, and (while not included in the phase III trial) significant morphologic dysplasia (≥50%) in at least two cell lineages. The optimal clinical role of CPX-351 in the treatment of patients with AML remains to be determined, but, given the CR and OS data, CPX-351 may become the new standard of care for older patients with t-AML/AML-MRC.</p></div><div class=section><a name=d33828e1049 class=n-a></a><h3 class=section-title>Enasidenib (IDH2 inhibitor)</h3><p class="" id=d33828e1054>Enasidenib (AG-221) is a selective, oral inhibitor of the mIDH2 enzyme. Approximately 12% of patients with AML have these mutations<sup><a href="#ref-58">58</a></sup>. In the setting of mIDH2, the oncometabolite D-2-hydroxyglutarate (2-HG) is generated rather than αKG. 2-HG inhibits TET protein activity, resulting in downstream DNA hypermethylation and a block in myeloid differentiation similar to the MDS phenotype of TET2 loss of function. The neomorphic mIDH2 enzyme is a promising drug target, and after much pre-clinical work<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>, the first-in-human phase I/II study of an IDH2 inhibitor (enasidenib), conducted by Stein <i>et al</i>. (including our center), showed an overall response rate (ORR) of 40.3% and a CR rate of about 20% (24.4% for IDH2-R172 and 17.7% for IDH2-R140 isoforms) in relapsed/refractory AML patients (176 patients, many heavily pre-treated)<sup><a href="#ref-61">61</a></sup>. The results of this dose escalation/expansion study led to the recent FDA approval of enasidenib for relapsed/refractory AML with mIDH2. The primary mechanism of response has been confirmed to be through myeloid differentiation<sup><a href="#ref-62">62</a></sup>, and a clinically significant but manageable differentiation syndrome can occur in these patients (7%)<sup><a href="#ref-61">61</a></sup>, similar to what has been more frequently observed in APL. Otherwise, the drug is generally well tolerated and grade 1–2 nausea/anorexia and indirect hyperbilirubinemia (grade 3–4 in 12%) are the most frequent side effects. The drug is approved at 100 mg orally daily. The dose was allowed to be increased to 150 or 200 mg daily for lack of response in the phase II portion of the study, but this would currently be off-label usage (of note, the maximum tolerated dose was not reached in the phase I portion at doses beyond 200 mg daily). The average duration of response is about 6 months, but there are some excellent responders with continuous remissions for more than 2 years. Interestingly, in most patients achieving CR, the IDH2 mutant clone persists in functioning neutrophils<sup><a href="#ref-62">62</a></sup>. While mIDH2 variant allele frequency (VAF) and the extent of 2-HG suppression do not appear to impact response rates, total mutational burden and the co-occurrence of RAS mutations have been associated with a <i>decreased</i> response to IDH2 inhibition<sup><a href="#ref-62">62</a></sup>. Combinations of enasidenib with induction chemotherapy in newly diagnosed mIDH2 AML patients<sup><a href="#ref-63">63</a></sup> and with HMAs in older/unfit newly diagnosed or relapsed/refractory mIDH2 AML patients are ongoing<sup><a href="#ref-64">64</a></sup> (ClinicalTrials.gov Identifier: NCT02719574).</p></div><div class=section><a name=d33828e1104 class=n-a></a><h3 class=section-title>Midostaurin (FLT3 inhibitor)</h3><p class="" id=d33828e1109>Midostaurin is a multi-targeted kinase inhibitor active in AML patients with an <i>FLT3</i> mutation. The drug was recently approved by the FDA on the basis of the randomized, placebo-controlled phase III RATIFY trial (Randomized AML Trial In FLT3 in patients less than 60 Years old) conducted in younger (18–59 years old) newly diagnosed AML patients with an <i>FLT3</i>-ITD or <i>FLT3</i>-tyrosine kinase domain (<i>FLT3</i>-TKD) mutation<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. Patients (n = 717) were randomly assigned (1:1) to receive midostaurin 50 mg orally twice daily or placebo on days 8–21 of standard induction (3+7 with 60 mg/m<sup>2</sup> daunorubicin) and consolidation (high-dose cytarabine). This was a large study and cooperative effort that screened over 3,000 patients, and patients were stratified according to <i>FLT3</i> mutation subtype (ITD versus TKD) and ITD-to-wild-type allele ratio (high versus low). Patients were allowed to receive allogeneic HSCT, and those who did not receive an allotransplant received maintenance midostaurin. There was improved OS and event-free survival (EFS) in the midostaurin-treated patients. The difference in median OS (74.7 versus 25.6 months; one-sided <i>p</i> = 0.009) appears quite large in favor of the midostaurin group; however, owing to the inflection points on the Kaplan-Meier curves, the authors acknowledged that the hazard ratio (HR) for death likely more accurately reflects the true clinical benefit (HR = 0.78, one-sided <i>p</i> = 0.009) (that is, a 22% reduction in death for the midostaurin-treated patients). This survival benefit persisted in patients censored for allogeneic HSCT, reminding us that some FLT3 patients, especially in the midostaurin era, can be cured without transplant. The adverse events occurring in both groups were expected and consistent with those patients receiving intensive chemotherapy experience. The only significant differences in grade 3 or higher toxicity between groups were anemia and rash, which were more common with midostaurin, and nausea, which was less common with midostaurin. Hematologic recovery of neutrophils and platelets were the same between groups. Lastly, it is important to note that patients did well in this study overall; 359 (50.1%) of 717 patients with <i>FLT3</i> mutations survived at a median follow-up of 59 months. Whether this was due to better supportive care, improvements in transplantation, or patient selection bias on clinical trials remains to be seen.</p></div><div class=section><a name=d33828e1148 class=n-a></a><h3 class=section-title>Gemtuzumab ozogamicin</h3><p class="" id=d33828e1153>GO is an antibody–drug conjugate that targets CD33, a cell surface antigen that is expressed on the blast cells in 90% or more of patients with AML<sup><a href="#ref-67">67</a></sup>. The antibody is covalently linked to calicheamicin, a potent DNA-damaging agent. Most of the cytotoxic payload remains conjugated to the antibody until it is internalized and cleaved by hydrolytic enzymes, but circulating free drug does pose a risk of extramedullary toxicity. GO was initially licensed by the FDA in 2000 for relapsed AML at a dose of 9 mg/m<sup>2</sup> for two doses on days 1 and 14 (single agent) but was withdrawn from the market in 2010 because of the risk of hepatic veno-occlusive disease (VOD), particularly in patients who previously had or went on to receive allogeneic HSCT<sup><a href="#ref-68">68</a></sup>. The risk of VOD was related to the time elapsed between GO and transplantation or vice versa<sup><a href="#ref-69">69</a></sup>. Since then, however, the drug has been further studied, primarily in Europe, at reduced, fractionated doses. With these modifications, several groups have now demonstrated satisfactory safety and efficacy data, leading to the drug’s re-approval in the US in 2017. Adverse side effects include myelosuppression, hepatotoxicity, tumor lysis syndrome (TLS), and infusion reactions. The drug now has three approved indications for AML on the basis of the following three studies:</p><p class="" id=d33828e1171>1. <span style="text-decoration: underline">ALFA-0701 study</span>: this 271-patient randomized phase III study examined the addition of GO to standard induction and consolidation chemotherapy (3+7) in patients with newly diagnosed <i>de novo</i> AML<sup><a href="#ref-70">70</a></sup>. The primary endpoint of median EFS was significantly longer in the GO versus the no GO arm: 17.3 versus 9.5 months (<i>p</i> ≤0.001). VOD occurred in 3% of patients in the GO arm and in none receiving standard of care.</p><p class="" id=d33828e1187>2. <span style="text-decoration: underline">AML-19 study</span>: this was a randomized phase III study examining single-agent GO induction (and maintenance) in 237 previously untreated AML patients not candidates for intensive chemotherapy (median age of 77 years)<sup><a href="#ref-71">71</a></sup>. Patients treated with GO had improved OS, and the HR for death was 0.69 (<i>p</i> = 0.005). The CR + complete response with incomplete blood recovery (CRi) rate with GO was 27%, and the clinical benefit rate—including partial remission (PR) and stable disease of more than 30 days—was 56.7%. Patients treated with GO experienced myelosuppression, but there was no excess non-hematologic toxicity—including febrile neutropenia, VOD, infection, and bleeding—making this a viable treatment option for older patients.</p><p class="" id=d33828e1200>3. <span style="text-decoration: underline">MyloFrance-1 study</span>: this non-randomized 57-patient phase II study evaluated single-agent GO re-induction in <i>de novo</i> AML patients with intermediate-risk (78%) or poor-risk (22%) cytogenetics in first relapse (prior HSCT excluded)<sup><a href="#ref-72">72</a></sup>. Patients received one course of GO 3.5 mg/m<sup>2</sup> on days 1, 4, and 7 (fractionated and lower cumulative dosing compared with prior studies in this population, which used 9 mg/m<sup>2</sup> on days 1 and 14). The CR rate in this study was 26%, and median relapse-free survival in these (CR2) patients was 11.6 months. Hematologic toxicity was expected and tolerable, and there was no grade 3 or greater liver toxicity and no VOD, including in patients who went on to receive HSCT.</p><p class="" id=d33828e1220>The FDA has re-approved GO for three indications on the basis of the three studies above, which as a whole used fractionated and lower doses of GO than did the trials that led to its initial approval in 2001. However, GO may add to myelotoxicity during induction, and there is still a risk of VOD, particularly peri-transplant, so caution should be taken with its use. The optimal dose and schedule of GO are still being assessed, particularly in combination with induction chemotherapy, and less may be better, particularly in patients with core-binding factor (CBF) abnormalities<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e1234>Novel investigational strategies</h2><p class="" id=d33828e1237>Some of the most promising novel therapies in AML include small-molecule inhibitors of epigenetic enzymes, inhibitors of anti-apoptotic proteins such as the B-cell leukemia/lymphoma-2 (BCL2) family, and immunotherapy, such as PD-1 axis inhibitors, bispecific antibodies to CD3 and CD123 (expressed in the majority of AML cells), and CAR-T cell approaches.</p><div class=section><a name=d33828e1240 class=n-a></a><h3 class=section-title>Venetoclax</h3><p class="" id=d33828e1245>Venetoclax (ABT-199) is a highly selective oral inhibitor of the anti-apoptotic protein BCL2 and is approved for treatment-resistant 17p-deleted chronic lymphocytic leukemia. AML stem and progenitor cells depend on BCL2 for survival, and pre-clinical studies have demonstrated significant activity in AML models<sup><a href="#ref-75">75</a></sup>. Clinically, venetoclax was first examined as a single agent in a phase II study of 32 patients with AML (relapsed/refractory or unfit for conventional chemotherapy)<sup><a href="#ref-76">76</a></sup>. The venetoclax dose was increased in a stepwise fashion to mitigate the risk of TLS (20 mg on day 1, 50 mg on day 2, 100 mg on day 3, 200 mg on day 4, 400 mg on day 5, and 800 mg on day 6 and thereafter), and TLS did not occur in this study. The ORR in this study was 19% (two CRs and four patients with CRi), all occurring in previously treated patients. Another six (19%) patients had a significant (≥50%) reduction in BM blast percentage. More recently, venetoclax has been combined with HMA therapy<sup><a href="#ref-77">77</a></sup> and low-dose ara-C (LDAC)<sup><a href="#ref-78">78</a></sup> in treatment-naïve older patients (not candidates for induction) with high response rates and apparent safety, although data are still emerging. A recent phase Ib study of 57 patients treated with venetoclax HMA combination showed a 61% combined CR/CRi rate<sup><a href="#ref-77">77</a></sup>. Given the impressive response rates of about 60 to 70% observed with both HMA and LDAC combinations, venetoclax has received breakthrough therapy designation by the FDA to accelerate its development as a frontline combination partner for older/unfit AML patients (both HMA and LDAC combinations).</p></div><div class=section><a name=d33828e1269 class=n-a></a><h3 class=section-title>Other FLT3 inhibitors</h3><p class="" id=d33828e1274>The FLT3 receptor tyrosine kinase drives cellular proliferation and survival through the JAK-STAT, MEK/MAPK, and PI3K signaling pathways. Both ITD and point mutations in the TKD occur in AML, resulting in constitutive activity of the enzyme. <i>FLT3</i>-ITD is one of the most common mutations in AML (~30%) and is associated in general with a poor prognosis<sup><a href="#ref-79">79</a>–<a href="#ref-81">81</a></sup>. Typically, patients have a high white blood cell count at presentation and are chemo-sensitive, usually achieving CR. However, relapse usually occurs without allogeneic HSCT, and patients rapidly become chemo-refractory. Co-occurring <i>NPM1</i> mutations somewhat ameliorate the prognosis of <i>FLT3</i>-ITD AML<sup><a href="#ref-82">82</a></sup>, placing patients in a more intermediate-risk category, whereas co-occurring <i>DNMT3A</i> mutations or trisomy 8 worsen the prognosis, as does a high <i>FLT3</i>-ITD allele burden, particularly in the absence of mutated <i>NPM1</i><sup><a href="#ref-9">9</a>,<a href="#ref-82">82</a></sup>. <i>FLT3</i>-TKD mutations (usually D835) occur in an additional 10% of patients (approximately), and the prognostic impact is less clear and is likely not as unfavorable as the ITD. Given the rapidly fatal nature of relapsed FLT3-mutant AML, FLT3 inhibitors have been in development for almost two decades. While FLT3 inhibitors have been shown to have clinical activity in AML and can serve as a bridge to allo-HSCT, there are still no approved FLT3 inhibitors for <i>relapsed</i>/<i>refractory</i> FLT3-AML. Sorafenib is a multi-kinase inhibitor that inhibits FLT3 along with vascular endothelial growth factor receptor and other kinases, and it is approved for hepatic, thyroid, and kidney cancer. Sorafenib is often used off-label in combination with azacitidine for relapsed/refractory or older/unfit FLT3-AML, given the lack of other good options for these patients outside of a clinical trial, and this use is supported by National Comprehensive Cancer Network guidelines based on a phase II trial of 37 evaluable patients with FLT3-AML showing an ORR of 46% with 10 CRi, six CR, and one PR<sup><a href="#ref-83">83</a></sup>. Median duration of response in this study was 2.3 months (range of 1–14.3 months), underscoring the fact that the emergence of treatment resistance to FLT3 inhibition is a frequent problem. Sorafenib has also shown promise as a maintenance therapy for FLT3-ITD-mutant AML post-transplant, and retrospective data show that it improves OS (HR 0.26, <i>p</i> = 0.021)<sup><a href="#ref-84">84</a></sup>. Other studies of newer-generation FLT3 inhibitors such as quizartinib, crenolanib, and gilteritinib are ongoing or completed. A problem with most FLT3 inhibitors is that, while they may be transiently effective against the FLT3-ITD and may serve as a bridge to allo-HSCT in some patients, acquired resistance-conferring point mutations at D835 (or other activation loop substitutions) or gatekeeper (F691) mutations commonly occur over a period of months, resulting in loss of response. Gilteritinib, an oral FLT3 and AXL inhibitor, was recently reported to have activity against some of these mutations. A phase I/II study in relapsed/refractory FLT3-mutated AML showed a 57.5% overall response rate and 47.2% composite CR rate—CR, CRi, and CR with incomplete platelet recovery (CRp)—in 106 patients receiving doses of 80 mg daily or higher<sup><a href="#ref-85">85</a></sup>. A phase III registration trial with gilteritinib is ongoing in relapsed/refractory FLT3-AML.</p></div><div class=section><a name=d33828e1339 class=n-a></a><h3 class=section-title>IDH1 inhibitors</h3><p class="" id=d33828e1344>Like the <i>IDH2</i> gene, the <i>IDH1</i> gene is mutated in AML. IDH1 resides primarily in the cytosol, whereas IDH2 is primarily mitochondrial. The phenotype of <i>IDH1</i> or <i>IDH2</i> mutant AML is similar, characterized by the gain-of-function, neomorphic mutant IDH activity producing 2-HG, which in turn impairs cellular differentiation. <i>IDH1</i> mutations (IDH1m) are slightly less common than IDH2 mutations in AML; the former are seen in about 8 to 10% of patients, mostly those with normal karyotype AML, and the most commonly co-occurring mutations are in the <i>NPM1</i>, <i>DNMT3A</i>, and <i>FLT3</i> genes<sup><a href="#ref-86">86</a></sup>. <i>IDH1</i> and <i>IDH2</i> mutations are mutually exclusive to each other and to TET2 and WT1 mutations. The first study using an IDH1 inhibitor (AG-120), a large phase I/II study, has now completed enrollment; response rates to AG-120 appear to be similar to those to enasidenib (AG-221). In the first 78 evaluable MDS/AML patients (most relapsed/refractory), the overall response rate was 38.5% with 14 CRs (17.9% of patients)<sup><a href="#ref-87">87</a></sup>. The side effect profile of AG-120 is similar to that of enasidenib (that is, it too is well tolerated). As with the IDH2 inhibitor, most patients achieving CR with AG-120 did not achieve IDH1 mutation clearance by next-generation sequencing (VAF ≥1%, median coverage 500×). As with IDH2 inhibitor therapy, differentiation-like syndrome can occur with IDH1 inhibitors, and it may be more common in patients receiving concomitant HMA therapy. Multiple studies of different IDH1 inhibitors are ongoing, including newer-generation IDH1 inhibitors and combinations of these agents (or AG-120) with HMAs and induction chemotherapy.</p></div><div class=section><a name=d33828e1389 class=n-a></a><h3 class=section-title>LSD1 inhibitors</h3><p class="" id=d33828e1394>In addition to IDH inhibitors, other new drugs targeting epigenetic modifications have strong therapeutic potential. Epigenetic enzymes such as DNMTs, histone deacetylases (HDACs), and histone methyltransferases/demethylases all represent bona fide targets for anti-cancer drug development and several have been discussed herein<sup><a href="#ref-40">40</a>,<a href="#ref-88">88</a></sup>. It is important to remember that epigenetic events play an essential role in promoting myeloid leukemogenesis and that epigenetic alterations occur far more frequently than genetic mutations in AML blasts. Treatment with DNA demethylating agents leads to clinical responses in about 20 to 30% of cases<sup><a href="#ref-89">89</a></sup>. Two HMAs (azacitidine and decitabine) are well known and approved for MDS, CMML, and low-blast AML in the US and Europe (and are also approved for older adults with more than 30% blasts in Europe). However, histone methylation and DNA methylation both play critical roles in transcriptional regulation. Notably, specific histone methyl marks coordinately regulate chromatin structure to activate (for example, H3K4me2) or inactivate (for example, H3K27me2) myeloid differentiation programs. Specifically, the removal of H3K4me2 is catalyzed by lysine-specific demethylase 1 (LSD1), which removes mono- and di-methyl marks on H3K4. LSD1 is highly expressed in patients with AML. Removal of these marks by LSD1 generally interferes with myeloid differentiation; therefore, inhibiting LSD1 may result in the restoration of myeloid gene expression, although this may be cell context dependent. LSD1 is being actively investigated as a drug target; LSD1 inhibitors have shown anti-leukemic activity (generally cytostatic) in pre-clinical models and may function as differentiating agents<sup><a href="#ref-90">90</a>,<a href="#ref-91">91</a></sup>. Early phase single-agent LSD1 inhibitor clinical trials are ongoing, and further studies combining LSD1 inhibitors with HMAs are being designed.</p><p class="" id=d33828e1415>In addition, LSD1 inhibitors have promising therapeutic potential when given in combination with ATRA. ATRA has revolutionized the treatment of APL, a subtype of AML (about 5–10% of all AML) characterized by the PML-RARα (PML-RARA) fusion protein, arising from a balanced translocation involving the <i>RARA</i> gene on chromosome 17 and the <i>PML</i> gene on chromosome 15. When given in combination with chemotherapy or arsenic trioxide, ATRA induces differentiation and ultimately cure in virtually all APL patients who do not die from early bleeding events<sup><a href="#ref-92">92</a></sup>. However, ATRA has little, if any, effect on differentiation or anti-leukemic activity in patients with non-APL AML. One of the underlying reasons for this lack of response to ATRA in non-APL AML is the failure to induce transcriptional activation of target genes such as <i>RARA</i>. However, LSD1 inhibition in combination with ATRA appears to unlock these transcriptional programs<sup><a href="#ref-93">93</a></sup>. Therefore, several LSD1 inhibitors are currently being studied with ATRA, including tranylcypromine (TCP) (Parnate<sup>®</sup>), an irreversible monoamine oxidase (MAO) inhibitor that is FDA approved as an antidepressant and anxiolytic agent. TCP has more recently been shown to inhibit LSD1, decreasing H3K4 methylation<sup><a href="#ref-94">94</a></sup>, and Schenk <i>et al</i>. have demonstrated that, when added to ATRA, TCP greatly potentiates the differentiation response in non-APL AML cell lines and primary patient samples, leading to decreased leukemia burden and elimination of leukemia-initiating cells<sup><a href="#ref-93">93</a></sup>. Given the availability of TCP, it has already been re-purposed in combination with ATRA for phase I clinical trials in both the US and Europe, which are currently accruing. More potent LSD1 inhibitors than TCP are being studied pre-clinically and have demonstrated greater differentiative effect in combination with ATRA<sup><a href="#ref-95">95</a></sup>.</p></div><div class=section><a name=d33828e1455 class=n-a></a><h3 class=section-title>BET bromodomain inhibitors</h3><p class="" id=d33828e1460>Bromodomain (BRD) and extra terminal (BET) family proteins are epigenetic readers that bind acetylated histones and facilitate the transcription of various oncogenes, such as <i>c</i>-<i>Myc</i>, primarily by regulating their super-enhancers. BRD4 inhibitors are being studied in different clinical trials in a variety of solid-organ and hematologic malignancies, including AML (ClinicalTrials.gov Identifier: NCT02711137). MYC is overexpressed in most AML samples (~70%), as are other BRD-regulated pathways such as Ras and Hedgehog<sup><a href="#ref-96">96</a></sup>. Pre-clinically, BRD inhibition has activity in AML cell lines, including FLT-ITD-mutated and MLL-rearranged cells, as well as in mouse xenograft models<sup><a href="#ref-97">97</a></sup>. Several clinical trials are ongoing in myeloid neoplasms, including combinations with HMAs<sup><a href="#ref-98">98</a></sup>.</p></div><div class=section><a name=d33828e1482 class=n-a></a><h3 class=section-title>Targeting mutant TP53</h3><p class="" id=d33828e1487>The TP53/chromosomal aneuploidy subtype of AML represents about 10 to 20% of AML<sup><a href="#ref-8">8</a></sup> and is enriched in older patients, many of whom have antecedent MDS or t-AML<sup><a href="#ref-10">10</a></sup>. TP53 alterations are common but not always present in complex karyotype AML (60%) and predict for even worse prognosis within this subgroup<sup><a href="#ref-99">99</a></sup>. Although CPX-351 has been approved for secondary-type AML (p53 status not known on the phase III trial) as previously discussed and may affect outcomes in this subgroup going forward, patients with TP53/aneuploidy historically fare extremely poorly even with allogeneic HSCT<sup><a href="#ref-99">99</a></sup>. Decitabine has shown some promise to bridge these patients to allo-HSCT, particularly the 10-day regimen, with high rates of blast clearance, but long-term outcomes with decitabine remain to be seen, and it has not been compared head-to-head with standard induction chemotherapy<sup><a href="#ref-49">49</a>,<a href="#ref-100">100</a></sup>.</p><p class="" id=d33828e1513>New agents are being developed for this very poor-risk subtype of AML. The neddylation (Nedd8) inhibitor pevonedistat has shown recent promise in this subgroup<sup><a href="#ref-50">50</a></sup>. Neddylation is a process similar to ubiquitination, is catalyzed by Nedd8-activating enzyme (NAE), and is required for cullin-ring ligase (CRL)-mediated degradation of various protein substrates. Inhibiting the polymerization of Nedd8 breaks down this process, resulting in the accumulation of cytotoxic substrates within the cell and apoptosis. In a phase I dose-escalation study of pevonedistat plus azacitidine in treatment-naïve older AML patients, the combination was well tolerated, ORR was 50% (20 CR, five CRi, and seven PR), and 63% of responders (20/32) responded during the first two cycles<sup><a href="#ref-101">101</a></sup>. In addition, four out of five patients with <i>TP53</i> mutations responded (CR/PR) with two maintaining response for more than 10 cycles. A randomized phase II study of pevonedistat (at the RP2D of 20 mg/m<sup>2</sup> intravenously on days 1, 3, and 5 of a 28-day cycle) with or without azacitidine (standard dose and schedule) in the same patient population has completed enrollment (ClinicalTrials.gov Identifier: NCT02610777), and a phase III study is ongoing (ClinicalTrials.gov Identifier: NCT03268954). In addition, for myeloid neoplasms with <i>TP53</i> point mutations, refolding agents (for example, APR-246) to restore the wild-type conformation of the TP53 protein are being studied in clinical trials (ClinicalTrials.gov Identifier: NCT03072043).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33828e1537>Conclusions</h2><p class="" id=d33828e1540>Improved understanding of the genetic and epigenetic alterations underlying AML development have refined prognostic algorithms and are starting to generate better treatment options for patients. Recently approved drugs have demonstrated improved outcomes in AML, and this is likely just the beginning as we continue to develop more individualized approaches to treat the different subtypes of AML with combinations of chemotherapy, kinase inhibitors, and epigenetic-targeted therapies. Recent therapeutic advances have largely resulted from improved delivery of chemotherapy with CPX-351 and GO. Mutation-targeted therapies for AML have also emerged with IDH2 and FLT3 inhibitors. The future of AML therapy lies in the rational combination of these agents, informed by pre-clinical research and selected for the right patient, and early phase clinical trials should incorporate more combinatorial and biomarker-driven arms early in their development.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d33828e1 class=n-a></a><h2 class=main-title id=d34172>Competing interests</h2><p class=metadata-entry><a name=d33828e90 class=n-a></a><p id=d33828e91> Justin Watts has served as a consultant and on the Speaker’s Bureau for Jazz Pharmaceuticals. He has received research funding from Takeda.</p></p></div><div class=back-section><a name=d33828e1 class=n-a></a><h2 class=main-title id=d34174>Grant information</h2><p>The authors receive support from a Leukemia and Lymphoma Society (LLS) Specialized Center of Research (SCOR) Grant (Stephen Nimer [principal investigator] and Justin Watts), NIH-NCI R01CA166835 (Stephen Nimer), NIH-NCI R21CA202488 (Justin Watts), and a University of Miami Clinical and Translational Science Institute KL2TR000461 Grant (Justin Watts).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d33828e1547 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d34516>References</h2><div class="section ref-list"><a name=d33828e1547 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d33828e1554 class=n-a></a><a target=xrefwindow id=d33828e1555><a target=xrefwindow id=d33828e1555 href="https://seer.cancer.gov/statfacts/html/amyl.htmlsimple"> https://seer.cancer.gov/statfacts/html/amyl.html</a></a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1160239"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1564 class=n-a></a>Juliusson G, Antunovic P, Derolf A, <i> et al.</i>: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. <i>Blood.</i> 2009; <b>113</b>(18): 4179–87. <a target=xrefwindow id=d33828e1575 href="http://www.ncbi.nlm.nih.gov/pubmed/19008455">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1578 href="http://dx.doi.org/10.1182/blood-2008-07-172007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1160239">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d33828e1591 class=n-a></a>Slovak ML, Kopecky KJ, Cassileth PA, <i> et al.</i>: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. <i>Blood.</i> 2000; <b>96</b>(13): 4075–83. <a target=xrefwindow id=d33828e1602 href="http://www.ncbi.nlm.nih.gov/pubmed/11110676">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d33828e1611 class=n-a></a>Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. <i>Blood.</i> 2005; <b>106</b>(4): 1154–63. <a target=xrefwindow id=d33828e1619 href="http://www.ncbi.nlm.nih.gov/pubmed/15870183">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1622 href="http://dx.doi.org/10.1182/blood-2005-01-0178">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d33828e1631 class=n-a></a>Burnett AK, Milligan D, Goldstone A, <i> et al.</i>: The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. <i>Br J Haematol.</i> 2009; <b>145</b>(3): 318–32. <a target=xrefwindow id=d33828e1642 href="http://www.ncbi.nlm.nih.gov/pubmed/19291085 ">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1645 href="http://dx.doi.org/10.1111/j.1365-2141.2009.07604.x">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d33828e1655 class=n-a></a>Burnett AK, Milligan D, Prentice AG, <i> et al.</i>: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. <i>Cancer.</i> 2007; <b>109</b>(6): 1114–24. <a target=xrefwindow id=d33828e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/17315155">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1669 href="http://dx.doi.org/10.1002/cncr.22496">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d33828e1678 class=n-a></a>Burnett AK, Russell NH, Kell J, <i> et al.</i>: European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. <i>J Clin Oncol.</i> 2010; <b>28</b>(14): 2389–95. <a target=xrefwindow id=d33828e1689 href="http://www.ncbi.nlm.nih.gov/pubmed/20385984">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1692 href="http://dx.doi.org/10.1200/JCO.2009.26.4242">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718012088"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1701 class=n-a></a>Cancer Genome Atlas Research Network, Ley TJ, Miller C, <i> et al.</i>: Genomic and epigenomic landscapes of adult <i>de novo</i> acute myeloid leukemia. <i>N Engl J Med.</i> 2013; <b>368</b>(22): 2059–74. <a target=xrefwindow id=d33828e1715 href="http://www.ncbi.nlm.nih.gov/pubmed/23634996">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1719 href="http://dx.doi.org/10.1056/NEJMoa1301689">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3767041">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718012088">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716547840"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1735 class=n-a></a>Patel JP, Gönen M, Figueroa ME, <i> et al.</i>: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <i>N Engl J Med.</i> 2012; <b>366</b>(12): 1079–89. <a target=xrefwindow id=d33828e1746 href="http://www.ncbi.nlm.nih.gov/pubmed/22417203">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1749 href="http://dx.doi.org/10.1056/NEJMoa1112304">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1753 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3545649">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716547840">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726406038"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1766 class=n-a></a>Papaemmanuil E, Gerstung M, Bullinger L, <i> et al.</i>: Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(23): 2209–21. <a target=xrefwindow id=d33828e1777 href="http://www.ncbi.nlm.nih.gov/pubmed/27276561">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1780 href="http://dx.doi.org/10.1056/NEJMoa1516192">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4979995">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726406038">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727506801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1797 class=n-a></a>Glass JL, Hassane D, Wouters BJ, <i> et al.</i>: Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. <i>Cancer Discov.</i> 2017; <b>7</b>(8): 868–83. <a target=xrefwindow id=d33828e1808 href="http://www.ncbi.nlm.nih.gov/pubmed/28408400">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1811 href="http://dx.doi.org/10.1158/2159-8290.CD-16-1032">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1815 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540802">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727506801">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d33828e1829 class=n-a></a>Meldi KM, Figueroa ME: Epigenetic deregulation in myeloid malignancies. <i>Transl Res.</i> 2015; <b>165</b>(1): 102–14. <a target=xrefwindow id=d33828e1837 href="http://dx.doi.org/10.1016/j.trsl.2014.04.012">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d33828e1846 class=n-a></a>Solary E, Bernard OA, Tefferi A, <i> et al.</i>: The <i>Ten-Eleven Translocation-2 (TET2)</i> gene in hematopoiesis and hematopoietic diseases. <i>Leukemia.</i> 2014; <b>28</b>(3): 485–96. <a target=xrefwindow id=d33828e1860 href="http://www.ncbi.nlm.nih.gov/pubmed/24220273">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1864 href="http://dx.doi.org/10.1038/leu.2013.337">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727756475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1873 class=n-a></a>Buscarlet M, Provost S, Zada YF, <i> et al.</i>: <i>DNMT3A</i> and <i>TET2</i> dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. <i>Blood.</i> 2017; <b>130</b>(6): 753–62. <a target=xrefwindow id=d33828e1891 href="http://www.ncbi.nlm.nih.gov/pubmed/28655780">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1894 href="http://dx.doi.org/10.1182/blood-2017-04-777029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727756475">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d33828e1907 class=n-a></a>Li Z, Cai X, Cai CL, <i> et al.</i>: Deletion of <i>Tet2</i> in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. <i>Blood.</i> 2011; <b>118</b>(17): 4509–18. <a target=xrefwindow id=d33828e1921 href="http://www.ncbi.nlm.nih.gov/pubmed/21803851">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1925 href="http://dx.doi.org/10.1182/blood-2010-12-325241">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1928 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3952630">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/12818959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e1937 class=n-a></a>Moran-Crusio K, Reavie L, Shih A, <i> et al.</i>: <i>Tet2</i> loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. <i>Cancer Cell.</i> 2011; <b>20</b>(1): 11–24. <a target=xrefwindow id=d33828e1951 href="http://www.ncbi.nlm.nih.gov/pubmed/21723200">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1955 href="http://dx.doi.org/10.1016/j.ccr.2011.06.001">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3194039">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/12818959">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d33828e1971 class=n-a></a>Hatlen MA, Arora K, Vacic V, <i> et al.</i>: Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. <i>J Exp Med.</i> 2016; <b>213</b>(1): 25–34. <a target=xrefwindow id=d33828e1982 href="http://www.ncbi.nlm.nih.gov/pubmed/26666262">PubMed Abstract </a> | <a target=xrefwindow id=d33828e1985 href="http://dx.doi.org/10.1084/jem.20150524">Publisher Full Text </a> | <a target=xrefwindow id=d33828e1989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4710200">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d33828e1999 class=n-a></a>Shih AH, Jiang Y, Meydan C, <i> et al.</i>: Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. <i>Cancer Cell.</i> 2015; <b>27</b>(4): 502–15. <a target=xrefwindow id=d33828e2010 href="http://www.ncbi.nlm.nih.gov/pubmed/25873173">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2013 href="http://dx.doi.org/10.1016/j.ccell.2015.03.009">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4518555">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729069992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2026 class=n-a></a>Cimmino L, Dolgalev I, Wang Y, <i> et al.</i>: Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. <i>Cell.</i> 2017; <b>170</b>(6): 1079–1095.e20. <a target=xrefwindow id=d33828e2037 href="http://www.ncbi.nlm.nih.gov/pubmed/28823558">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2040 href="http://dx.doi.org/10.1016/j.cell.2017.07.032">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2044 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5755977">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729069992">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d33828e2057 class=n-a></a>Bejar R, Lord A, Stevenson K, <i> et al.</i>: <i>TET2</i> mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood.</i> 2014; <b>124</b>(17): 2705–12. <a target=xrefwindow id=d33828e2071 href="http://www.ncbi.nlm.nih.gov/pubmed/25224413">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2075 href="http://dx.doi.org/10.1182/blood-2014-06-582809">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2078 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4208285">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d33828e2087 class=n-a></a>Carbuccia N, Trouplin V, Gelsi-Boyer V, <i> et al.</i>: Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. <i>Leukemia.</i> 2010; <b>24</b>(2): 469–73. <a target=xrefwindow id=d33828e2098 href="http://www.ncbi.nlm.nih.gov/pubmed/19865112">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2101 href="http://dx.doi.org/10.1038/leu.2009.218">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d33828e2110 class=n-a></a>Makishima H, Jankowska AM, McDevitt MA, <i> et al.</i>: CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. <i>Blood.</i> 2011; <b>117</b>(21):e198–206. <a target=xrefwindow id=d33828e2121 href="http://www.ncbi.nlm.nih.gov/pubmed/21346257">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2124 href="http://dx.doi.org/10.1182/blood-2010-06-292433">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2128 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3110035">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d33828e2137 class=n-a></a>Gelsi-Boyer V, Trouplin V, Roquain J, <i> et al.</i>: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. <i>Br J Haematol.</i> 2010; <b>151</b>(4): 365–75. <a target=xrefwindow id=d33828e2148 href="http://www.ncbi.nlm.nih.gov/pubmed/20880116">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2151 href="http://dx.doi.org/10.1111/j.1365-2141.2010.08381.x">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d33828e2161 class=n-a></a>Brecqueville M, Rey J, Bertucci F, <i> et al.</i>: Mutation analysis of <i>ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12</i>, and <i>TET2</i> in myeloproliferative neoplasms. <i>Genes Chromosomes Cancer.</i> 2012; <b>51</b>(8): 743–55. <a target=xrefwindow id=d33828e2179 href="http://www.ncbi.nlm.nih.gov/pubmed/22489043">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2182 href="http://dx.doi.org/10.1002/gcc.21960">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727623220"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2191 class=n-a></a>Micol JB, Pastore A, Inoue D, <i> et al.</i>: ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nat Commun.</i> 2017; <b>8</b>: 15429. <a target=xrefwindow id=d33828e2202 href="http://www.ncbi.nlm.nih.gov/pubmed/28516957">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2205 href="http://dx.doi.org/10.1038/ncomms15429">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2209 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5454368">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727623220">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726038475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2222 class=n-a></a>Inoue D, Matsumoto M, Nagase R, <i> et al.</i>: Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. <i>Exp Hematol.</i> 2016; <b>44</b>(33): 172–6.e1. <a target=xrefwindow id=d33828e2233 href="http://www.ncbi.nlm.nih.gov/pubmed/26700326">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2236 href="http://dx.doi.org/10.1016/j.exphem.2015.11.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726038475">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718173278"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2249 class=n-a></a>Abdel-Wahab O, Gao J, Adli M, <i> et al.</i>: Deletion of Asxl1 results in myelodysplasia and severe developmental defects <i>in vivo</i>. <i>J Exp Med.</i> 2013; <b>210</b>(12): 2641–59. <a target=xrefwindow id=d33828e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/24218140">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2267 href="http://dx.doi.org/10.1084/jem.20131141">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3832937">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718173278">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d33828e2283 class=n-a></a>Wang J, Li Z, He Y, <i> et al.</i>: Loss of <i>Asxl1</i> leads to myelodysplastic syndrome-like disease in mice. <i>Blood.</i> 2014; <b>123</b>(4): 541–53. <a target=xrefwindow id=d33828e2297 href="http://www.ncbi.nlm.nih.gov/pubmed/24255920">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2301 href="http://dx.doi.org/10.1182/blood-2013-05-500272">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2304 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3901067">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d33828e2313 class=n-a></a>Sun XJ, Man N, Tan Y, <i> et al.</i>: The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. <i>Front Oncol.</i> 2015; <b>5</b>: 108. <a target=xrefwindow id=d33828e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/26075180">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2327 href="http://dx.doi.org/10.3389/fonc.2015.00108">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2331 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4443728">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d33828e2341 class=n-a></a>Dancy BM, Cole PA: Protein lysine acetylation by p300/CBP. <i>Chem Rev.</i> 2015; <b>115</b>(6): 2419–52. <a target=xrefwindow id=d33828e2349 href="http://www.ncbi.nlm.nih.gov/pubmed/25594381">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2352 href="http://dx.doi.org/10.1021/cr500452k">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2355 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4378506">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1003340"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2364 class=n-a></a>Brownell JE, Zhou J, Ranalli T, <i> et al.</i>: Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. <i>Cell.</i> 1996; <b>84</b>(6): 843–51. <a target=xrefwindow id=d33828e2375 href="http://www.ncbi.nlm.nih.gov/pubmed/8601308">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2378 href="http://dx.doi.org/10.1016/S0092-8674(00)81063-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1003340">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8990963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2391 class=n-a></a>Pasqualucci L, Dominguez-Sola D, Chiarenza A, <i> et al.</i>: Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <i>Nature.</i> 2011; <b>471</b>(7337): 189–95. <a target=xrefwindow id=d33828e2402 href="http://www.ncbi.nlm.nih.gov/pubmed/21390126">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2405 href="http://dx.doi.org/10.1038/nature09730">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3271441">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8990963">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d33828e2422 class=n-a></a>Wang L, Gural A, Sun XJ, <i> et al.</i>: The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. <i>Science.</i> 2011; <b>333</b>(6043): 765–9. <a target=xrefwindow id=d33828e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/21764752">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2436 href="http://dx.doi.org/10.1126/science.1201662">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2440 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3251012">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d33828e2449 class=n-a></a>Yan G, Eller MS, Elm C, <i> et al.</i>: Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. <i>J Invest Dermatol.</i> 2013; <b>133</b>(10): 2444–52. <a target=xrefwindow id=d33828e2460 href="http://www.ncbi.nlm.nih.gov/pubmed/23698071">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2463 href="http://dx.doi.org/10.1038/jid.2013.187">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4380234">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d33828e2476 class=n-a></a>Santer FR, Höschele PP, Oh SJ, <i> et al.</i>: Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. <i>Mol Cancer Ther.</i> 2011; <b>10</b>(9): 1644–55. <a target=xrefwindow id=d33828e2487 href="http://www.ncbi.nlm.nih.gov/pubmed/21709130">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2490 href="http://dx.doi.org/10.1158/1535-7163.MCT-11-0182">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d33828e2500 class=n-a></a>Cheng G, Liu F, Asai T, <i> et al.</i>: Loss of p300 accelerates MDS-associated leukemogenesis. <i>Leukemia.</i> 2017; <b>31</b>(6): 1382–90. <a target=xrefwindow id=d33828e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/27881875">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2514 href="http://dx.doi.org/10.1038/leu.2016.347">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5667352">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731383984"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2527 class=n-a></a>Lasko LM, Jakob CG, Edalji RP, <i> et al.</i>: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. <i>Nature.</i> 2017; <b>550</b>(7674): 128–32. <a target=xrefwindow id=d33828e2538 href="http://www.ncbi.nlm.nih.gov/pubmed/28953875">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2541 href="http://dx.doi.org/10.1038/nature24028">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6050590">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731383984">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d33828e2558 class=n-a></a>Shirakawa K, Wang L, Man N, <i> et al.</i>: Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. <i>eLife.</i> 2016; <b>5</b>: pii: e11156. <a target=xrefwindow id=d33828e2569 href="http://www.ncbi.nlm.nih.gov/pubmed/27244239">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2572 href="http://dx.doi.org/10.7554/eLife.11156">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2576 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4931907">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d33828e2585 class=n-a></a>Lin YW, Slape C, Zhang Z, <i> et al.</i>: <i>NUP98-HOXD13</i> transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. <i>Blood.</i> 2005; <b>106</b>(1): 287–95. <a target=xrefwindow id=d33828e2599 href="http://www.ncbi.nlm.nih.gov/pubmed/15755899">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2603 href="http://dx.doi.org/10.1182/blood-2004-12-4794">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2606 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1201424">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d33828e2615 class=n-a></a>Xu H, Menendez S, Schlegelberger B, <i> et al.</i>: Loss of p53 accelerates the complications of myelodysplastic syndrome in a <i>NUP98-HOXD13</i>-driven mouse model. <i>Blood.</i> 2012; <b>120</b>(15): 3089–97. <a target=xrefwindow id=d33828e2629 href="http://www.ncbi.nlm.nih.gov/pubmed/22927245">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2633 href="http://dx.doi.org/10.1182/blood-2012-01-405332">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3471517">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d33828e2645 class=n-a></a>Taggart J, Ho TC, Amin E, <i> et al.</i>: MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. <i>Nat Commun.</i> 2016; <b>7</b>: 10739. <a target=xrefwindow id=d33828e2656 href="http://www.ncbi.nlm.nih.gov/pubmed/26898884">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2659 href="http://dx.doi.org/10.1038/ncomms10739">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4764878">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d33828e2673 class=n-a></a>Picaud S, Fedorov O, Thanasopoulou A, <i> et al.</i>: Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Res.</i> 2015; <b>75</b>(23): 5106–19. <a target=xrefwindow id=d33828e2684 href="http://www.ncbi.nlm.nih.gov/pubmed/26552700">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2687 href="http://dx.doi.org/10.1158/0008-5472.CAN-15-0236">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2691 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4948672">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726441607"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2700 class=n-a></a>Zucconi BE, Luef B, Xu W, <i> et al.</i>: Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112. <i>Biochemistry.</i> 2016; <b>55</b>(27): 3727–34. <a target=xrefwindow id=d33828e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/27332697">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2714 href="http://dx.doi.org/10.1021/acs.biochem.6b00480">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2718 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007619">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726441607">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d33828e2731 class=n-a></a>Castelli G, Pelosi E, Testa U: Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. <i>Onco Targets Ther.</i> 2017; <b>11</b>: 131–55. <a target=xrefwindow id=d33828e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/29343972">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2742 href="http://dx.doi.org/10.2147/OTT.S145971">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2745 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5749389">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d33828e2754 class=n-a></a>Greenblatt SM, Liu F, Nimer SD: Arginine methyltransferases in normal and malignant hematopoiesis. <i>Exp Hematol.</i> 2016; <b>44</b>(6): 435–41. <a target=xrefwindow id=d33828e2762 href="http://www.ncbi.nlm.nih.gov/pubmed/27026282">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2765 href="http://dx.doi.org/10.1016/j.exphem.2016.03.009">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d33828e2774 class=n-a></a>Vu LP, Perna F, Wang L, <i> et al.</i>: PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. <i>Cell Rep.</i> 2013; <b>5</b>(6): 1625–38. <a target=xrefwindow id=d33828e2785 href="http://www.ncbi.nlm.nih.gov/pubmed/24332853">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2788 href="http://dx.doi.org/10.1016/j.celrep.2013.11.025">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4073674">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d33828e2801 class=n-a></a>Penebre E, Kuplast KG, Majer CR, <i> et al.</i>: Identification of a First-in-Class PRMT5 Inhibitor with Potent <i>in Vitro</i> and <i>in Vivo</i> Activity in Preclinical Models of Mantle Cell Lymphoma. <i>Blood.</i> 2014; <b>124</b>(21): 438. <a target=xrefwindow id=d33828e2819 href="http://www.bloodjournal.org/content/124/21/438">Reference Source</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d33828e2829 class=n-a></a>Kaushik S, Liu F, Veazey KJ, <i> et al.</i>: Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of <i>MLL</i>-rearranged AML. <i>Leukemia.</i> 2018; <b>32</b>(2): 499–509. <a target=xrefwindow id=d33828e2843 href="http://www.ncbi.nlm.nih.gov/pubmed/28663579">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2847 href="http://dx.doi.org/10.1038/leu.2017.206">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5865447">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727103206"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2859 class=n-a></a>Welch JS, Petti AA, Miller CA, <i> et al.</i>: TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>N Engl J Med.</i> 2016; <b>375</b>(21): 2023–36. <a target=xrefwindow id=d33828e2870 href="http://www.ncbi.nlm.nih.gov/pubmed/27959731">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2873 href="http://dx.doi.org/10.1056/NEJMoa1605949">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2877 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5217532">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727103206">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d33828e2890 class=n-a></a>Swords RT, Erba HP, DeAngelo DJ, <i> et al.</i>: Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. <i>Br J Haematol.</i> 2015; <b>169</b>(4): 534–43. <a target=xrefwindow id=d33828e2901 href="http://www.ncbi.nlm.nih.gov/pubmed/25733005">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2904 href="http://dx.doi.org/10.1111/bjh.13323">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d33828e2913 class=n-a></a>Mayer LD, Harasym TO, Tardi PG, <i> et al.</i>: Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. <i>Mol Cancer Ther.</i> 2006; <b>5</b>(7): 1854–63. <a target=xrefwindow id=d33828e2924 href="http://www.ncbi.nlm.nih.gov/pubmed/16891472">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2927 href="http://dx.doi.org/10.1158/1535-7163.MCT-06-0118">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d33828e2936 class=n-a></a>Feldman EJ, Lancet JE, Kolitz JE, <i> et al.</i>: First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. <i>J Clin Oncol.</i> 2011; <b>29</b>(8): 979–85. <a target=xrefwindow id=d33828e2947 href="http://www.ncbi.nlm.nih.gov/pubmed/21282541">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2950 href="http://dx.doi.org/10.1200/JCO.2010.30.5961">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4520927">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732151003"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e2963 class=n-a></a>Nikanjam M, Capparelli EV, Lancet JE, <i> et al.</i>: Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. <i>Cancer Chemother Pharmacol.</i> 2018; <b>81</b>(1): 171–8. <a target=xrefwindow id=d33828e2974 href="http://www.ncbi.nlm.nih.gov/pubmed/29167924">PubMed Abstract </a> | <a target=xrefwindow id=d33828e2977 href="http://dx.doi.org/10.1007/s00280-017-3484-5">Publisher Full Text </a> | <a target=xrefwindow id=d33828e2981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5756117">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732151003">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d33828e2995 class=n-a></a>Kim HP, Gerhard B, Harasym TO, <i> et al.</i>: Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. <i>Exp Hematol.</i> 2011; <b>39</b>(7): 741–50. <a target=xrefwindow id=d33828e3006 href="http://www.ncbi.nlm.nih.gov/pubmed/21530609">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3009 href="http://dx.doi.org/10.1016/j.exphem.2011.04.001">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d33828e3018 class=n-a></a>Lim WS, Tardi PG, Dos Santos N, <i> et al.</i>: Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. <i>Leuk Res.</i> 2010; <b>34</b>(9): 1214–23. <a target=xrefwindow id=d33828e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/20138667">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3032 href="http://dx.doi.org/10.1016/j.leukres.2010.01.015">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d33828e3041 class=n-a></a>Tardi P, Johnstone S, Harasym N, <i> et al.</i>: <i>In vivo</i> maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. <i>Leuk Res.</i> 2009; <b>33</b>(1): 129–39. <a target=xrefwindow id=d33828e3055 href="http://www.ncbi.nlm.nih.gov/pubmed/18676016">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3059 href="http://dx.doi.org/10.1016/j.leukres.2008.06.028">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d33828e3068 class=n-a></a>Lancet JE, <i> et al.</i>: Final results of a phase III randomized trial of VYXEOS™ (CPX-351) versus 7 + 3 in older patients with newly diagnosed high-risk (secondary) AML. Oral presentation at: American Society of Clinical Oncology Annual Meeting; June 3–7, 2016.</span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d33828e3080 class=n-a></a>Stein EM: IDH2 inhibition in AML: Finally progress? <i>Best Pract Res Clin Haematol.</i> 2015; <b>28</b>(2–3): 112–5. <a target=xrefwindow id=d33828e3088 href="http://www.ncbi.nlm.nih.gov/pubmed/26590767">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3091 href="http://dx.doi.org/10.1016/j.beha.2015.10.016">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6799956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3100 class=n-a></a>Figueroa ME, Abdel-Wahab O, Lu C, <i> et al.</i>: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. <i>Cancer Cell.</i> 2010; <b>18</b>(6): 553–67. <a target=xrefwindow id=d33828e3111 href="http://www.ncbi.nlm.nih.gov/pubmed/21130701">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3114 href="http://dx.doi.org/10.1016/j.ccr.2010.11.015">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3118 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4105845">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6799956">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14263961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3132 class=n-a></a>Lu C, Ward PS, Kapoor GS, <i> et al.</i>: IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature.</i> 2012; <b>483</b>(7390): 474–8. <a target=xrefwindow id=d33828e3143 href="http://www.ncbi.nlm.nih.gov/pubmed/22343901">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3146 href="http://dx.doi.org/10.1038/nature10860">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3478770">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14263961">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727693321"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3163 class=n-a></a>Stein EM, DiNardo CD, Pollyea DA, <i> et al.</i>: Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia. <i>Blood.</i> 2017; <b>130</b>(6): 722–31. <a target=xrefwindow id=d33828e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/28588020">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3181 href="http://dx.doi.org/10.1182/blood-2017-04-779405">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5572791">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727693321">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727693322"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3197 class=n-a></a>Amatangelo MD, Quek L, Shih A, <i> et al.</i>: Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood.</i> 2017; <b>130</b>(6): 732–41. <a target=xrefwindow id=d33828e3208 href="http://www.ncbi.nlm.nih.gov/pubmed/28588019">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3211 href="http://dx.doi.org/10.1182/blood-2017-04-779447">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3215 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5553578">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727693322">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d33828e3228 class=n-a></a>Stein EM, DiNardo CD, Mims AS, <i> et al.</i>: Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial. <i>Blood.</i> 2017; <b>130</b>: 726, ASH. <a target=xrefwindow id=d33828e3239 href="http://www.bloodjournal.org/content/130/Suppl_1/726">Reference Source</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d33828e3248 class=n-a></a>Dinardo CD, Stein AS, Fathi AT, <i> et al.</i>: Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood.</i> 2017; <b>130</b>: 639, ASH. <a target=xrefwindow id=d33828e3259 href="http://www.bloodjournal.org/content/130/Suppl_1/639">Reference Source</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727742055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3268 class=n-a></a>Stone RM, Mandrekar SJ, Sanford BL, <i> et al.</i>: Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. <i>N Engl J Med.</i> 2017; <b>377</b>(5): 454–64. <a target=xrefwindow id=d33828e3282 href="http://www.ncbi.nlm.nih.gov/pubmed/28644114">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3286 href="http://dx.doi.org/10.1056/NEJMoa1614359">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3289 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5754190">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727742055">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d33828e3303 class=n-a></a>Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv.</i> 2017;2(4):444-453. <i>Blood Adv.</i> 2018; <b>2</b>(7): 787. <a target=xrefwindow id=d33828e3314 href="http://www.ncbi.nlm.nih.gov/pubmed/29618463">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3317 href="http://dx.doi.org/10.1182/bloodadvances.2018018481">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5894266">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d33828e3330 class=n-a></a>de Propris MS, Raponi S, Diverio D, <i> et al.</i>: High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (<i>NPM1</i>) mutation. <i>Haematologica.</i> 2011; <b>96</b>(10): 1548–51. <a target=xrefwindow id=d33828e3344 href="http://www.ncbi.nlm.nih.gov/pubmed/21791474">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3348 href="http://dx.doi.org/10.3324/haematol.2011.043786">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3186318">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d33828e3360 class=n-a></a>Larson RA, Sievers EL, Stadtmauer EA, <i> et al.</i>: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer.</i> 2005; <b>104</b>(7): 1442–52. <a target=xrefwindow id=d33828e3371 href="http://www.ncbi.nlm.nih.gov/pubmed/16116598">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3374 href="http://dx.doi.org/10.1002/cncr.21326">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d33828e3383 class=n-a></a>Wadleigh M, Richardson PG, Zahrieh D, <i> et al.</i>: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood.</i> 2003; <b>102</b>(5): 1578–82. <a target=xrefwindow id=d33828e3394 href="http://www.ncbi.nlm.nih.gov/pubmed/12738663">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3397 href="http://dx.doi.org/10.1182/blood-2003-01-0255">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717952822"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3406 class=n-a></a>Castaigne S, Pautas C, Terré C, <i> et al.</i>: Effect of gemtuzumab ozogamicin on survival of adult patients with <i>de-novo</i> acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet.</i> 2012; <b>379</b>(9825): 1508–16. <a target=xrefwindow id=d33828e3420 href="http://www.ncbi.nlm.nih.gov/pubmed/22482940">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3424 href="http://dx.doi.org/10.1016/S0140-6736(12)60485-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717952822">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726102457"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3437 class=n-a></a>Amadori S, Suciu S, Selleslag D, <i> et al.</i>: Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>J Clin Oncol.</i> 2016; <b>34</b>(9): 972–9. <a target=xrefwindow id=d33828e3448 href="http://www.ncbi.nlm.nih.gov/pubmed/26811524">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3451 href="http://dx.doi.org/10.1200/JCO.2015.64.0060">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726102457">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d33828e3465 class=n-a></a>Taksin AL, Legrand O, Raffoux E, <i> et al.</i>: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. <i>Leukemia.</i> 2007; <b>21</b>(1): 66–71. <a target=xrefwindow id=d33828e3476 href="http://www.ncbi.nlm.nih.gov/pubmed/17051246">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3479 href="http://dx.doi.org/10.1038/sj.leu.2404434">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726178132"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3488 class=n-a></a>Burnett A, Cavenagh J, Russell N, <i> et al.</i>: Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m<sup>2</sup> with 6 mg/m<sup>2</sup> in the NCRI AML17 Trial. <i>Haematologica.</i> 2016; <b>101</b>(6): 724–31. <a target=xrefwindow id=d33828e3506 href="http://www.ncbi.nlm.nih.gov/pubmed/26921360">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3509 href="http://dx.doi.org/10.3324/haematol.2016.141937">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3512 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5013968">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726178132">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726907049"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3525 class=n-a></a>Khan N, Hills RK, Virgo P, <i> et al.</i>: Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. <i>Leukemia.</i> 2017; <b>31</b>(5): 1059–68. <a target=xrefwindow id=d33828e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/27795558">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3539 href="http://dx.doi.org/10.1038/leu.2016.309">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5419583">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726907049">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d33828e3556 class=n-a></a>Pan R, Hogdal LJ, Benito JM, <i> et al.</i>: Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. <i>Cancer Discov.</i> 2014; <b>4</b>(3): 362–75. <a target=xrefwindow id=d33828e3567 href="http://www.ncbi.nlm.nih.gov/pubmed/24346116">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3570 href="http://dx.doi.org/10.1158/2159-8290.CD-13-0609">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3975047">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726638619"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3583 class=n-a></a>Konopleva M, Pollyea DA, Potluri J, <i> et al.</i>: Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. <i>Cancer Discov.</i> 2016; <b>6</b>(10): 1106–17. <a target=xrefwindow id=d33828e3594 href="http://www.ncbi.nlm.nih.gov/pubmed/27520294">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3597 href="http://dx.doi.org/10.1158/2159-8290.CD-16-0313">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5436271">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726638619">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732499596"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3614 class=n-a></a>DiNardo CD, Pratz KW, Letai A, <i> et al.</i>: Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncol.</i> 2018; <b>19</b>(2): 216–28. <a target=xrefwindow id=d33828e3625 href="http://www.ncbi.nlm.nih.gov/pubmed/29339097">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3628 href="http://dx.doi.org/10.1016/S1470-2045(18)30010-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732499596">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d33828e3642 class=n-a></a>Lei A, Strickland SA, Roboz GJ, <i> et al.</i>: Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood.</i> ASH, Abstract 616. 2017; <b>130</b>: 890. <a target=xrefwindow id=d33828e3653 href="http://www.bloodjournal.org/content/130/Suppl_1/890?sso-checked=true">Reference Source</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d33828e3662 class=n-a></a>Kindler T, Lipka DB, Fischer T: FLT3 as a therapeutic target in AML: still challenging after all these years. <i>Blood.</i> 2010; <b>116</b>(24): 5089–102. <a target=xrefwindow id=d33828e3670 href="http://www.ncbi.nlm.nih.gov/pubmed/20705759">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3673 href="http://dx.doi.org/10.1182/blood-2010-04-261867">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d33828e3682 class=n-a></a>Kottaridis PD, Gale RE, Frew ME, <i> et al.</i>: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. <i>Blood.</i> 2001; <b>98</b>(6): 1752–9. <a target=xrefwindow id=d33828e3693 href="http://www.ncbi.nlm.nih.gov/pubmed/11535508">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3696 href="http://dx.doi.org/10.1182/blood.V98.6.1752 ">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d33828e3705 class=n-a></a>Whitman SP, Archer KJ, Feng L, <i> et al.</i>: Absence of the wild-type allele predicts poor prognosis in adult <i>de novo</i> acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of <i>FLT3</i>: a cancer and leukemia group B study. <i>Cancer Res.</i> 2001; <b>61</b>(19): 7233–9. <a target=xrefwindow id=d33828e3723 href="http://www.ncbi.nlm.nih.gov/pubmed/11585760">PubMed Abstract </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727041738"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3732 class=n-a></a>Döhner H, Estey E, Grimwade D, <i> et al.</i>: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood.</i> 2017; <b>129</b>(4): 424–47. <a target=xrefwindow id=d33828e3743 href="http://www.ncbi.nlm.nih.gov/pubmed/27895058">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3746 href="http://dx.doi.org/10.1182/blood-2016-08-733196">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3750 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5291965">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727041738">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d33828e3763 class=n-a></a>Ravandi F, Alattar ML, Grunwald MR, <i> et al.</i>: Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and <i>FLT-3</i> internal tandem duplication mutation. <i>Blood.</i> 2013; <b>121</b>(23): 4655–62. <a target=xrefwindow id=d33828e3777 href="http://www.ncbi.nlm.nih.gov/pubmed/23613521">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3781 href="http://dx.doi.org/10.1182/blood-2013-01-480228">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3674666">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726774118"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3794 class=n-a></a>Brunner AM, Li S, Fathi AT, <i> et al.</i>: Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i>FLT3</i>-ITD acute myeloid leukaemia in first complete remission. <i>Br J Haematol.</i> 2016; <b>175</b>(3): 496–504. <a target=xrefwindow id=d33828e3808 href="http://www.ncbi.nlm.nih.gov/pubmed/27434660">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3812 href="http://dx.doi.org/10.1111/bjh.14260">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3815 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5083189">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726774118">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d33828e3828 class=n-a></a>Levis MJ, Perl AE, Jessica K, <i> et al.</i>: Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). <i>J Clin Oncol.</i> 2015; <b>33</b>(15_suppl): 7003. <a target=xrefwindow id=d33828e3839 href="http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.7003">Reference Source</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732034518"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3848 class=n-a></a>Ragon BK, DiNardo CD: Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia. <i>Curr Hematol Malig Rep.</i> 2017; <b>12</b>(6): 537–46. <a target=xrefwindow id=d33828e3856 href="http://www.ncbi.nlm.nih.gov/pubmed/29064021">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3859 href="http://dx.doi.org/10.1007/s11899-017-0418-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732034518">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d33828e3872 class=n-a></a>DiNardo CD, de Botton S, Stein EM, <i> et al.</i>: Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. <i>Blood.</i> 2016; <b>128</b>: 1070. <a target=xrefwindow id=d33828e3883 href="http://investor.agios.com/static-files/ec3fad7d-f0ae-47c6-a58c-e28bbbfd7ea3">Reference Source</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d33828e3892 class=n-a></a>Abdel-Wahab O, Patel J, Levine RL: Clinical implications of novel mutations in epigenetic modifiers in AML. <i>Hematol Oncol Clin North Am.</i> 2011; <b>25</b>(6): 1119–33. <a target=xrefwindow id=d33828e3900 href="http://www.ncbi.nlm.nih.gov/pubmed/22093580">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3903 href="http://dx.doi.org/10.1016/j.hoc.2011.09.013">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1158168"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e3912 class=n-a></a>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, <i> et al.</i>: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. <i>Lancet Oncol.</i> 2009; <b>10</b>(3): 223–32. <a target=xrefwindow id=d33828e3923 href="http://www.ncbi.nlm.nih.gov/pubmed/19230772">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3926 href="http://dx.doi.org/10.1016/S1470-2045(09)70003-8">Publisher Full Text </a> | <a target=xrefwindow id=d33828e3930 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4086808">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1158168">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d33828e3944 class=n-a></a>Berglund L, Björling E, Oksvold P, <i> et al.</i>: A genecentric Human Protein Atlas for expression profiles based on antibodies. <i>Mol Cell Proteomics.</i> 2008; <b>7</b>(10): 2019–27. <a target=xrefwindow id=d33828e3955 href="http://www.ncbi.nlm.nih.gov/pubmed/18669619">PubMed Abstract </a> | <a target=xrefwindow id=d33828e3958 href="http://dx.doi.org/10.1074/mcp.R800013-MCP200">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d33828e3967 class=n-a></a>Kruger RG, Mohammad H, Smitheman K, <i> et al.</i>: Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia. <i>Blood.</i> 2013; <b>122</b>: 3964. <a target=xrefwindow id=d33828e3978 href="http://www.bloodjournal.org/content/122/21/3964.short">Reference Source</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d33828e3987 class=n-a></a>Lo-Coco F, Avvisati G, Vignetti M, <i> et al.</i>: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>N Engl J Med.</i> 2013; <b>369</b>(2): 111–21. <a target=xrefwindow id=d33828e3998 href="http://www.ncbi.nlm.nih.gov/pubmed/23841729">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4001 href="http://dx.doi.org/10.1056/NEJMoa1300874">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/714147800"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e4010 class=n-a></a>Schenk T, Chen WC, Göllner S, <i> et al.</i>: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. <i>Nat Med.</i> 2012; <b>18</b>: 605–11. <a target=xrefwindow id=d33828e4021 href="http://www.ncbi.nlm.nih.gov/pubmed/22406747">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4024 href="http://dx.doi.org/10.1038/nm.2661">Publisher Full Text </a> | <a target=xrefwindow id=d33828e4028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3539284">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/714147800">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d33828e4041 class=n-a></a>Dart RC: Medical Toxicology. Philadelphia: Lippincott Williams and Wilkins. 2003; <b>1</b>: 2304.</span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d33828e4053 class=n-a></a>Swords RT, Perez A, Rodriguez A, <i> et al.</i>: The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML. <i>Blood.</i> 2015; <b>126</b>: 460. <a target=xrefwindow id=d33828e4064 href="http://www.bloodjournal.org/content/126/23/460?sso-checked=true">Reference Source</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d33828e4074 class=n-a></a>Salvatori B, Iosue I, Djodji Damas N, <i> et al.</i>: Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. <i>Genes Cancer.</i> 2011; <b>2</b>(5): 585–92. <a target=xrefwindow id=d33828e4085 href="http://www.ncbi.nlm.nih.gov/pubmed/21901171">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4088 href="http://dx.doi.org/10.1177/1947601911416357">Publisher Full Text </a> | <a target=xrefwindow id=d33828e4092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3161419">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727657498"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e4101 class=n-a></a>Braun T, Gardin C: Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). <i>Expert Opin Investig Drugs.</i> 2017; <b>26</b>(7): 803–11. <a target=xrefwindow id=d33828e4109 href="http://www.ncbi.nlm.nih.gov/pubmed/28541716">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4112 href="http://dx.doi.org/10.1080/13543784.2017.1335711">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727657498">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d33828e4125 class=n-a></a>Forero-Torres A, Rosen S, Smith DC, <i> et al.</i>: Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies. <i>Blood.</i> ASH. 2017; <b>130</b>: 4048. <a target=xrefwindow id=d33828e4136 href="http://www.bloodjournal.org/content/130/Suppl_1/4048">Reference Source</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d33828e4145 class=n-a></a>Rücker FG, Schlenk RF, Bullinger L, <i> et al.</i>: <i>TP53</i> alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood.</i> 2012; <b>119</b>(9): 2114–21. <a target=xrefwindow id=d33828e4159 href="http://www.ncbi.nlm.nih.gov/pubmed/22186996">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4163 href="http://dx.doi.org/10.1182/blood-2011-08-375758">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d33828e4172 class=n-a></a>Blum W, Garzon R, Klisovic RB, <i> et al.</i>: Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(16): 7473–8. <a target=xrefwindow id=d33828e4186 href="http://www.ncbi.nlm.nih.gov/pubmed/20368434">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4190 href="http://dx.doi.org/10.1073/pnas.1002650107">Publisher Full Text </a> | <a target=xrefwindow id=d33828e4193 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2867720">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732528755"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33828e4202 class=n-a></a>Swords RT, Coutre S, Maris MB, <i> et al.</i>: Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. <i>Blood.</i> 2018; <b>131</b>(13): 1415–24. <a target=xrefwindow id=d33828e4213 href="http://www.ncbi.nlm.nih.gov/pubmed/29348128">PubMed Abstract </a> | <a target=xrefwindow id=d33828e4216 href="http://dx.doi.org/10.1182/blood-2017-09-805895">Publisher Full Text </a> | <a target=xrefwindow id=d33828e4220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5909884">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732528755">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1196/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1196/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Sylvester Comprehensive Cancer Center and Miller School of Medicine, University of Miami, Miami, Florida, USA<br/> <p> <div class=margin-bottom> Justin Watts <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Writing – Original Draft Preparation </div> <div class=margin-bottom> Stephen Nimer <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1196/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 06 Aug 2018, 7:1196 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14116.1">https://doi.org/10.12688/f1000research.14116.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Watts J and Nimer S. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15353 data-id=14116 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14116.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1196/v1/pdf?article_uuid=67b78820-765c-43f1-a69e-691ec0708ff9" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14116.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Watts J and Nimer S. Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1196 (<a href="https://doi.org/10.12688/f1000research.14116.1" target=_blank>https://doi.org/10.12688/f1000research.14116.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14116 id=mobile-track-article-signin-14116 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14116?target=/articles/7-1196/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15353 /> <input name=articleId type=hidden value=14116 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Richard M. Stone</strong>, Dana Farber Cancer Institute, Harvard Medical School, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Christopher S. Hourigan</strong>, Myeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Bjorn T. Gjertsen</strong>, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Norway </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1196/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1196/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37155-36497></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37154-36496></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37153-36495></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1196/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>06 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Richard M. Stone</strong>, Dana Farber Cancer Institute, Harvard Medical School, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Christopher S. Hourigan</strong>, Myeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Bjorn T. Gjertsen</strong>, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Norway </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1196/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1196/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the understanding and...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1196/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1196/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1196/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Watts J and Nimer S');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1196/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1196",
            templates : {
                twitter : "Recent advances in the understanding and treatment of acute myeloid.... Watts J and Nimer S, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1196/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the understanding and treatment of acute myeloid leukemia", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the understanding and treatment of acute myeloid leukemia", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14116/15353")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15353");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36496": 0,
                           "36497": 0,
                           "36495": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f40e55ce-bf4a-4d60-8be4-2d96c32d89a9";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1196.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1196.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1196.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1196.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1196.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>